Centre for Innovation Progress Report

Transcription

Centre for Innovation
Progress Report
2014–2015
Published on June 29, 2015
Table of Contents
Executive summary
3
Overview of the Centre for Innovation
4
Objective
4
Expertise
4
Programs and projects
4
Research and development progress
5
Safety and sufficiency of the blood supply
5
Red blood cells
7
Platelets
10
Plasma, plasma products and plasma product replacement
11
Hematopoietic stem cells
12
Organ and tissue transplantation
13
Building capacity in transfusion and transplantation
14
Salary support
14
Education and training
15
Networking opportunities
20
Leveraging expertise through collaborations
21
Research and Education Network
21
Canadian Blood Utilization Collaborative
21
International Collaboration for Transfusion Medicine Guidelines
22
Alliance of Blood Operators
22
Risk-Based Decision Making Framework
23
Governance
23
References cited
24
Appendix I: Funded projects
i
Appendix II: Publications
vii
Appendix III: Health Canada Financial Contribution
xxii
Canadian Blood Services’ Centre for Innovation – Progress Report 2014–2015
2
Executive summary
The Centre for Innovation at Canadian Blood Services (the Centre) supports a safe, effective, and responsive
system of blood and related biologics for Canada. Through its multi-faceted activities, the Centre fosters and
supports relevant discovery and applied research, and facilitates the dissemination and application of created
knowledge. These activities promote the creation and translation of new knowledge into new and enhanced
practices, services, and technologies for the benefit of Canadian patients and the health-care system, now and in
the future.
The Centre for Innovation employs 11 principal investigators, cross-appointed to Canadian academic institutions,
and actively engages with Canadian Blood Services’ medical, epidemiology and supply chain staff. In 2014–
2015, this internal network was complemented by 27 external Canadian investigators who received funding from
the Centre to complete research studies or mentor trainees at their academic institutions. Through targeted
partnerships, the Centre’s network expands nationally and internationally. Over the last year, it formalized or
renewed 31 partnerships with industry, academia and not-for-profit organizations and associations.
The Centre for Innovation achievement highlights for 2014–2015 include:
 254 peer-reviewed publications, including articles in high-impact journals such as Blood, the Journal of
Clinical Investigation, the Journal of Immunology, and Thrombosis and Haemostasis. The average Hindex of 24 of the Centre’s core investigators reflects their productivity and citation impact.
 24 technical reports shared within Canadian Blood Services and with partners. Subject-matter expertise
and data included in these reports informed product and process improvements.
 14 professionals formally trained through its national training program.
 Over 200 oral and poster presentations at national and international conferences.
 Over 80 major education events organized or supported, attracting an estimated 7,000 professionals. These
included the LearnTransfusion webinar series, the Canadian Blood Services Annual International
Symposium, and the Red Cell Club Meeting.
 Three Health Canada licence amendments supported to achieve process improvements while also
maintaining safety and quality:
o Removing the requirement to balance centrifuges prior to whole blood centrifugation.
o Removing the confidential unit exclusion step from the blood collection procedure.
o Changing the Macopharma whole blood collection set and introducing the Macopharma platelet
pooling set.
 Provision of evidence-based data to the Canadian Standards Association that informed changes in red
blood cell storage standards.
 Contributions to the execution of several clinical trials, including the PREPAReS trial which will provide
the necessary information for the licensing of the pathogen inactivation technology Mirasol in Canada.
 Publication of systematic reviews and clinical guidelines to influence clinical practice. These include
guidelines for platelet utilization by the International Collaboration for Transfusion Medicine Guidelines
and by the AABB.
 Establishment of the Canadian Blood Utilization Collaborative to optimize blood utilization to improve
patient outcomes in a cost-effective manner.
3
Overview of the Centre for Innovation
Objective
Through its Centre for Innovation, Canadian Blood Services conducts and facilitates research and education
activities in transfusion and transplantation science and medicine. This report describes the progress the Centre
has made during fiscal year 2014–2015 and highlights its key achievements as they relate to the Centre’s goal of
contributing to the safety, quality and supply of blood and related biologics.
Expertise
Eleven principal investigators (bolded names throughout report) are core to the Centre for Innovation scientific
and process engineering expertise. Employees of Canadian Blood Services, they are tightly linked to our
organization and aware of the system’s research needs, overall goals and strategy. In particular, the investigations
led by the Centre’s product and process development investigators address key issues raised by our supply chain.
Furthermore, the cross-appointments of our core investigators at Canadian academic institutions create a bridge
and leverage resources available through academic institutions.
Supplementing the group of core investigators, the Centre engages with 29 Canadian Blood Services medical
experts and epidemiologists (bolded names throughout report). This group provides the medical expertise to the
network.
This internal network is strengthened by contributions from external investigators. In 2014–2015, there were 27
Canadian Blood Services adjunct scientists and Canadian academic researchers who led a research project
funded by the Centre’s research and training programs. The Centre's network also expands nationally and
internationally through partnerships with industry, academia, and not-for-profit organizations and associations.
Programs and projects
The Centre for Innovation develops a series of research and education programs to achieve its goal of creating
new knowledge in areas of significance and to disseminate this knowledge. Centre employees administer these
programs while leveraging Canadian Blood Services’ financial, legal, IT, communication and human resources
services.
In 2014–2015, through the Centre’s competitive research and training programs, the research group funded 51
research projects, 29 trainee awards and three Program Support Awards for Canadian transfusion medicine and
science research (Appendix 1). The product and process development group worked on 54 research and
investigational studies supporting our supply chain or with industry partners (Appendix 1). The knowledge
mobilization group organized or supported 81 education events, maintained its transfusion education website and
enhanced some of its primary educational tools.
The Centre for Innovation plays a leadership role in the establishment of significant collaborative projects. The
Risk-Based Decision Making Framework initiative was completed during the year, while the International
Collaboration for Transfusion Medicine Guidelines successfully published its first set of guidelines. Finally, a
new initiative, the Canadian Blood Utilization Collaborative, was established to optimize blood utilization to
improve patient outcomes in a cost-effective manner.
The successes of these projects and programs are highlighted throughout this report. These successes were made
possible by the continued funding received by the Centre for Innovation from Health Canada, the provincial and
territorial ministries of health, and our partners. The blood donors who contribute to our research are also
gratefully acknowledged.
4
Research and development progress
Canadian Blood Services must maintain the safety, quality and sufficiency of the blood and blood products
supply for Canadian patients. The blood and blood product supply chain is a complex process involving many
steps (Fig. 1). The knowledge created through the Centre for Innovation’s research and development programs
contributes to this process at multiple levels. This section of the report presents the Centre’s research and
development achievements for 2014–2015, including highlights of the impact of these achievements on the
safety, quality and sufficiency of the blood, blood products, and hematopoietic stem cells supply.
Figure 1: The vein-to vein path of blood and blood products for transfusion and transplantation
Safety and sufficiency of the blood supply
Under the leadership of Drs. Margaret Fearon, Mindy Goldman, and Sheila O’Brien, Canadian Blood
Services carries out comprehensive surveillance of bloodborne pathogens to monitor for changing trends in
known pathogens and to identify the risks associated with new or emerging pathogens. Within Canadian Blood
Services, the team works closely with the regulatory and quality groups, and leverages the expertise, testing and
research capacity available in our National Testing Laboratory. The team also collaborates extensively with
national and international partners. Surveillance information allows Canadian Blood Services to put additional
safeguards in place to reduce any risk to recipients of blood products.
In Canadian Blood Services’ 2014 Surveillance Report, the epidemiology and surveillance group reported that
the rates of tested transmissible disease per 100,000 donations continues to be very low.1 Through rigorous
methodology, the group estimated that the residual risk of a transfusion-transmitted infection also remains very
low. This data confirms the safety of the blood supply for the viruses we screen. Through this report, residual
risk information is also made available to physicians and their patients to inform their transfusion decisions. The
2014 report also highlighted potential risks to the blood supply associated with emerging parasites and viruses,
including Babesia microti, Hepatitis E, Chikungunya, and Ebola.
In collaboration with Dr. Gilles Delage from Héma-Québec, Dr. Fearon evaluated the seroprevalence of Babesia
microti and Hepatitis E virus in Canadian blood donors. Antibody testing for Babesia microti showed no
evidence of babesiosis in the almost 15,000 blood donors tested. Hepatitis E DNA testing using polymerase
chain reaction was performed on all donors and antibody testing was performed on a subset. A Hepatitis E
seroprevalence rate of 5.9 per cent was found, although no evidence of active infection has been observed
(0 DNA-positive donors). The results of these studies indicate there is no evidence to support implementation of
new donor testing policies or procedures for these bloodborne pathogens at this time, although ongoing
surveillance and additional research is needed.2-4
Starting in late 2013 and continuing through 2014, a large outbreak of a mosquito-borne infection, Chikungunya
virus, occurred in the Caribbean, extending into South and Central America. This was the first outbreak of
Chikungunya documented in the Americas. Although no cases of transfusion-related transmission have been
reported to date, Canadian Blood Services conducted research to evaluate the risk associated with this virus. Dr.
Fearon interacted with the Public Health Agency of Canada National Microbiology Laboratory, blood providers
and other international groups to monitor the infection rates in different countries. In collaboration with Dr.
O'Brien’s group, they also completed a travel survey of 8,908 blood donors. Data from the travel survey, as well
as the natural history of Chikungunya virus, was used to estimate the risk of collecting a donation from an
infected donor. Given that the risk was extremely low (less than one in six million donations), and that there are
no reports of Chikungunya virus ever being transmitted by transfusion, there is currently no evidence that any
intervention to address risk from Chikungunya virus is warranted.
5
A large outbreak of Ebola virus in West Africa prompted Canadian Blood Services to put together contingency
plans to address risk from potentially infected donors who may have come in contact with cases in Canada.
Donors returning from West Africa are already deferred for 12 months for malaria risk and so do not pose a risk
to blood safety. Under the leadership of Dr. Fearon, Canadian Blood Services developed information for donors
and staff to address risk in the unlikely event of an infection acquired in Canada.
Working with an international group, Dr. O’Brien led a study to examine the relationship between
epidemiologic data, public environment and operational feasibility in the "evolution" of malaria-risk-reduction
policies in different countries. The focus was on selective testing policies and deferral-only policies, as used in
Canada. The greatest risk of malaria is from former residents of endemic countries, whereas the greatest
operational impact is from short-term travellers who have a very low risk of malaria. The malaria-risk appears to
be well-managed by either selective testing or deferral-only policies. However, selective testing has the
advantage of impacting fewer donors for a shorter period. Importantly, the group observed that additions and
revisions had been made to all policies in response to concerns. The group was concerned that this sporadic
"evolution" resulted in different policies in each of the participating countries, and that if policies were to be
developed afresh they would not necessarily be those currently in place.5 The participation of Canadian Blood
Services in international studies such as this one prepares our organization for potential future changes in this
area.
In 2013, Canadian Blood Services implemented a new eligibility policy to allow blood donation from “men who
have had sex with men” (MSM) more than five years ago. Drs. O’Brien and Goldman continue to monitor the
impact of the policy on the safety and sufficiency of the blood supply. To date the rate of detection of HIVpositive donors after implementation of the new policy has not increased. 6 A large anonymous survey of male
donors was completed in April 2015 to assess donor compliance to the new policy before and after
implementation. Many male donors in the pre-implementation survey did not support the previous policy, under
which men who had had sex with a man even one time since 1977 were ineligible to donate blood. In particular,
young donors felt that a man who has had sex with a man should be allowed to donate as long as he meets all
other criteria. The group will continue to monitor the impact of the new policy and the compliance of blood
donors with this policy. The group provided a study report to Health Canada to inform regulators. Canadian
Blood Services also continues to discuss this contentious issue in the literature.7 Finally, in early 2015, netCAD,
Canadian Blood Services' research development facility, held a "rainbow clinic" to engage with donors who may
be affected by the policy and to encourage individuals who are ineligible to donate blood to the main blood
supply due to the MSM policy to donate blood for research purposes. During the course of the day, participants
had the opportunity to learn about the research projects supported by or conducted at netCAD and to donate their
blood to research. Highlighted in many media outlets, the rainbow clinic succeeded in engaging ineligible donors
with Canadian Blood Services.
Cytomegalovirus (CMV) is a common virus infecting most people during their lifetime, but rarely causing illness
in the healthy population. However, in some patients (e.g., organ transplant recipients), CMV can cause serious
illness or even death. The use of leukofiltration to reduce the number of white blood cells eliminates almost all
the risk of acquiring CMV from blood transfusion. However, a very low risk of infection remains.
In 2001, recommendations for the use of CMV-negative blood products (e.g., products that test negative for
CMV) for high-risk populations were developed. However, variability in their interpretation and application has
led to disparate local policies among both hospitals and blood operators, and wide variability across provinces.
To gather information that could inform development of a national policy, Drs. Dana Devine and Lani
Lieberman (of the University Health Network and a recent graduate of our transfusion medicine residency
program) convened an international forum to gather information around the wide range of practices related to
donor testing of CMV, the use of CMV-negative products in specialized populations, and the impact of this
product line on inventory management.8 This information provides a snapshot of the variation in the standard of
care in various jurisdictions. Finally, Drs. Fearon and O’Brien are collaborating in a large CMV study with Dr.
Jutta Preiksaitis (University of Alberta) to evaluate various testing modalities and to compare CMV positivity in
transfused organ recipients and blood donors. Preliminary results will be presented in the coming year.
6
While ensuring a sufficient blood supply is important to blood operators, this cannot be achieved at the detriment
of donor health. Drs. Goldman and O’Brien previously reported that a significant proportion of donors have low
or absent iron stores, which may lead to significant health risks.9, 10 In the last year, Canadian Blood Services has
worked to educate donors on iron deficiency and to better screen donors at risk. All donors who are ineligible to
donate blood as a result of low hemoglobin levels now receive a letter advising them to visit their physicians to
identify and correct the cause of low hemoglobin levels. Drs. Goldman and O’Brien have assessed donor
understanding of this letter and the actions donors take as a result of it. Unfortunately, while donors understand
the letter and the reason they are ineligible to donate, few donors take action to increase their iron stores.11
Canadian Blood Services is currently conducting a study to assess the operational feasibility of measuring ferritin
levels in donors. The data will be used to assess the effectiveness and operational feasibility of various potential
interventions to inform policy decision-making to protect our donors.
Prior to blood donation, Canadian Blood Services donors must complete a health history questionnaire and
confidentially indicate whether they think their donation should not be used. The confidential unit exclusion
(CUE) process was introduced into the blood collection procedure in Canada in the 1980s as a mechanism for
donors to confidentially indicate that they believed their blood may not be safe. However, it has been shown that
CUE does not contribute to blood safety in Canada, as a result of improvements in the donor screening process,
improvements in public heath, and advances in donor testing for human immunodeficiency virus (HIV) and other
infectious diseases. It has also been shown that those individuals who should be selecting the “do not use my
blood” option are not, while hundreds of donors who have no risk are selecting the discard option in the CUE in
error. Based on evidence collected by Drs. Goldman and O’Brien, Canadian Blood Services submitted and
received a licence amendment change from Health Canada to remove the CUE step from the blood collection
procedure, streamlining the blood collection process without affecting blood safety.12
The Centre for Innovation product and process development group undertakes investigations that generate the
evidence needed to improve Canadian Blood Services’ operations. In 2014, the group was instrumental in the
selection of the new collection bags required by Canadian Blood Services. By performing comprehensive quality
measurements, the group made recommendations for the selection of bags that would meet our quality control
standards.13, 14 This evidence was used to obtained a Health Canada licence amendment for the introduction of
new whole blood and platelet collection bags.15 The successful implementation of the new bags was completed
in early 2015. The product and process development group informed another licence amendment to Health
Canada that led to a manufacturing process improvement. Canadian Blood Services no longer requires the
routine balancing of centrifuges prior to whole blood centrifugation.16 The elimination of this step improves
efficiencies without impacting the quality of blood products.
Adequate donor skin disinfection is important to ensure the safety of blood components. Currently, Canadian
Blood Services uses the Chloraprep swabstick produced by CareFusion as the primary method to disinfect donor
skin. For donors with hypersensitivity to chlorhexidine, a two-step method, also produced by CareFusion, is
used. CareFusion has informed our organization that the production of the alternative two-step method will be
suspended later in 2015. Therefore, to ensure the continuity of the blood supply, Canadian Blood Services needs
to identify another alternative skin disinfection method for the approximately three per cent of donations where
the two-step method is used. Drs. Goldman and Sandra Ramirez-Arcos conducted a study to evaluate two
alternative methods. The results led to the selection of one method which will be implemented by Canadian
Blood Services in 2015.17
Red blood cells
Red blood cell units are the most common blood
product Canadian Blood Services distributes to
hospitals. One of the major challenges in the
production of red blood cell units is red blood cell
storage lesions, or changes in red blood cells
observed over time. Red blood cell lesions are
thought to affect oxygen delivery and thus may
have clinical implications.
Red blood cells are manufactured from
whole blood and stored for up to 42 days
at 1-6°C prior to transfusion. Canadian Blood
Services distributes ~800,000 units annually.
7
Current regulations permit red blood cells to be stored for up to 42 days. This regulation is thought to minimize
red blood cell storage lesions. However, whether these lesions matter clinically is heavily debated. Retrospective
studies have produced conflicting results and questioned the quality of “older blood” — blood that is closer to
the end of its 42-day shelf life. In 2015, the University of Ottawa Centre for Transfusion Research, supported by
the Centre for Innovation, completed the Age of Blood Evaluation (ABLE) trial. This landmark study
prospectively compared the clinical outcomes of critically ill adult patients transfused with “fresh blood” (blood
stored for less than seven days) to those transfused with “standard blood.” The study showed that transfusion
with “fresh blood” was not associated with a reduction in in-hospital mortality.18 Similarly, the McMaster
Transfusion Research Program, also with support from the Centre, retrospectively evaluated the effect of age of
blood on in-hospital mortality in patients with cardiovascular diagnoses. This study also found no association
between the age of blood and in-hospital mortality.19 These results support the Age of Red Blood Cells in
Premature Infants study published by the Ottawa group in 2012 and the recently completed RECESS study (see
report at Transfusion News). While the evidence is reassuring that standard-issue red blood cells are not
clinically different from fresher units, further research is needed. In particular, additional clinical situations must
be studied.
While current clinical evidence suggests there is no need for blood operators to shorten the shelf life for red
blood cells, Canadian Blood Services investigated the impact a decrease in the storage time for red blood cells
would have on its inventory and its distribution network. Dr. John Blake, from the product and process
development group, completed modelling work and presented at various venues.20-22 His work shows that a shelf
life of 14 days or less is likely to cause significant challenges for hospitals and for blood operators. With this
work, Canadian Blood Services is well prepared should a change in the storage time for red blood cells become
necessary. Dr. Blake received the Best Paper Award at the 2014 Industrial and System Engineering Research
Conference for this work.
To meet the demand for red blood cells locally, Canadian Blood Services regularly transfers red blood cell units
between its distribution sites. Dr. Blake developed a model to evaluate policies for transferring red blood cells
between sites. Based on his analysis, he identified simple rules that could potentially lower transport costs while
ensuring product availability.23, 24 With no studies in the literature tackling this type of problem, Dr. Blake’s
work is novel and will inform the optimization of Canadian Blood Services' inventory network.
Canadian standards require that red blood cells must not be exposed to room temperature for more than
30 minutes with each removal from storage. This “30-minute rule” is meant to minimize chances of bacterial
growth and limit hemolysis (or degradation of the red blood cells). Drs. Sandra Ramirez-Arcos and Jason
Acker have extensively evaluated the effect of room temperature exposure of more than 30 minutes on bacterial
growth and the quality of red blood cells. Their work, conducted in collaboration with Dr. Louis Thibault of
Héma-Québec, led to the amendment of the Canadian Standard Association standard. The new standard, which
will be published later this year, will permit the uncontrolled temperature exposure time for red blood cells to be
increased to 60 minutes.25, 26 This amendment will minimize red blood cell discards, especially at hospitals,
without compromising the quality or safety of the product. This standard change is expected to lead to savings
for the blood system.
Regulatory quality standards for red blood cell products include the requirements to have less than 0.8 per cent
hemolysis in the bag, to have sufficient volume and red cell mass, to be leukocyte reduced, to be sterile, and to
limit storage to a period of 42 days at 1–6°C. However, as our understanding of red blood cell products evolves,
so does our thinking on how to evaluate the quality of the product. Canadian Blood Services implemented the
Quality Monitoring Program. Led by Craig Jenkins, this unique program developed a series of biological
markers associated with each of our blood products to better understand their quality parameters, going beyond
regulatory requirements. Through the program, Jenkins and Dr. Acker were able to compare the quality of red
blood cell components produced before and after the implementation of semi-automated component production
at Canadian Blood Services. While the overall quality of the components was similar before and after the change
in production method, the results indicate that red blood cell products manufactured by different methods are not
equivalent.27 To further evaluate the effects of different manufacturing processes on red blood cell quality, Drs.
8
Acker and Dana Devine, with collaborators from Blood Systems Inc. (U.S.) compared the characteristics of red
blood cell concentrates produced by nine different processing methods and showed significant differences among
products.28 This data suggests that further research is required to evaluate the impact manufacturing processes
may have on the clinical outcomes of transfusion. These studies also raise the importance of controlling for
differences in manufacturing processes when performing clinical studies. Canadian Blood Services' Centre for
Innovation is currently partnering with the University of Ottawa Centre for Transfusion Research and the
McMaster Transfusion Research Program to investigate the impact of manufacturing processes and donor
characteristics on transfusion recipient outcomes.29
In collaboration with Dr. Mark Scott, Dr. Hongshen Ma (University of British Columbia) funded through an
operating grant has developed a device to determine red blood cell deformability changes that occur during
storage in blood bags. This device could be used to identify high-quality and low-quality units, using a very
small volume sample.30, 31 Such technology may change the way red blood cells are assessed prior to transfusion.
In a similar approach, Dr. Devine collaborated with Drs. Robert Turner and Michael Blades (University of
British Columbia) to apply Raman spectroscopy to develop a method to measure changes in red blood cell units
during storage without entering the unit and breaking sterility.32 Although presently at proof of concept, these
technologies are being adapted to hand-held instruments that would be adaptable to the hospital blood bank
environment. Drs. Acker and Michael Kolios (Ryerson University) are developing new approaches that would
allow for the assessment of red blood cell structure and their oxygen carrying capacity. Although preliminary,
their research suggests that photoacoustic imaging combined with spectroscopy may be useful in assessing these
parameters without entering the red blood cell unit.33
While red blood cell transfusions are considered to be safe, some patients exhibit mild to severe reactions. These
reactions arise as the patient’s immune system recognizes one or more of the more than 300 minor blood group
antigens present on the donor red blood cells, leading to the production of antibodies (alloantibodies). Patients
who are chronically transfused can develop so many alloantibodies that it is impossible to find red blood cell
units that can be transfused without causing harm. Researchers funded through the Centre are exploring several
approaches to address this challenge. In 2014, Dr. Jayachandran Kizhakkedathu (University of British Columbia)
described the development of a robust and universal technique that efficiently converts A, B, and AB red blood
cells to universal (O) donor red blood cells.34 While this technique has been described before, Dr.
Kizhakkedathu’s research team reduced the amounts of enzyme required for such conversions by more than 400fold. This enhancement will facilitate the translation of this technology to the clinic. This work was highlighted
in Transfusion News. Dr. Scott’s approach to the alloimmunization challenge is to identify ways to fool the
immune system by camouflaging the non-ABO red blood cell antigens.35 In the last year, Dr. Scott worked with
Canadian Blood Services' Centre for Innovation to develop a strategy to facilitate the emergency use of this
innovative product in these rare clinical situations described above.
New curative therapies, instead of symptomatic treatment offered through transfusions, would be advantageous
to alloimmunized patients. Dr. Marie Trudel (Université de Montréal), with funding from an operating grant, is
examining the molecular mechanisms involved in red blood cell differentiation.36, 37 Understanding the genes
involved in the transition between fetal (in the fetus) to adult hemoglobin will allow the development of
therapeutic approaches that may genetically correct diseases such as thalassemia and sickle cell disease.
Researchers funded through the 2014 operating grant competitions are exploring alternative approaches to red
blood cell transfusion. Alternatives that would no longer require collection from blood donors, such as synthetic
hemoglobin molecules, could provide a safe and unlimited supply for patients in need. Dr. Ronald Kluger
(University of Toronto) is altering human hemoglobin to develop a universal stable and sterile oxygen carrier.
His team developed methods to efficiently produce the oxygen carrier.38 In the coming year, they will evaluate
the compound in animal models with collaborators at Harvard. Dr. Thomas Ming Swi Chang (McGill
University) is also exploring the development of a human hemoglobin complex. They have tested their
compound in an animal model and demonstrated its efficacy in the treatment of hemorrhagic shock.39 In the
coming year, they will develop methods to produce the compound efficiently.
In an effort to improve product quality and patient safety, Canadian Blood Services produces washed red blood
9
cell concentrates for transfusion recipients who have a history of severe transfusion reactions. In 2013, the ACP215 cell processor was implemented at Canadian Blood Services to wash red blood cell concentrates, replacing
the COBE 2991 processor. In the past year, Dr. Acker, in collaboration with Dr. Barbara Hannach and
investigators at University Health Network, performed an observational clinical study to examine the efficacy
and safety of transfused washed red blood cell concentrates produced using the COBE 2991 processor compared
to those produced using the ACP-215 processor. The study found no differences on patient outcomes between
the two red cell products. However, because ACP-215 processed cells can be stored for longer than those
processed with the COBE 2991, the change in process has led to improved inventory management by Canadian
Blood Services and the hospital.40 Furthermore, the study found that fewer units were transfused per transfusion
episode, reducing patient exposure to red blood cell products and thus improving patient outcome.
Platelets
Platelets are small, circulating blood cells that play
a key role in the formation of blood clots. A
number of medical conditions are associated with a
decrease in platelet counts. To manage the
symptoms of these conditions, patients are
transfused with platelets.
Platelets are manufactured from whole
blood or apheresis collections and stored
for up to five days at 20–24°C with
continuous agitation prior transfusion. Canadian
Blood Services distributes ~115,000 doses
annually.
Unlike other blood products, platelets must be
stored at room temperature. This requirement increases the risk of bacterial growth if the unit is contaminated.
While transfusion reactions due to contaminated platelets are rare, they remain a challenge for the industry as
they can be fatal.
Dr. Sandra Ramirez-Arcos is an expert in bacteria and bacterial biofilms. Her development group supports
Canadian Blood Services in developing appropriate processes to minimize bacterial contamination. 41, 42 The first
line of defense against bacterial contamination of platelets is disinfection of the donor’s skin before donation.
However, her group has shown that biofilm-forming skin bacteria are more resistant to skin disinfection than
free-floating bacteria. This finding suggests that current procedures for disinfecting donor skin may be
inadequate and may explain why, despite current efforts, a proportion of platelets (~1:5,000) are contaminated
with bacteria. 43, 44 This research may lead to the development of new skin disinfection products that would
effectively kill biofilm-forming skin bacteria.
From the early days of platelet transfusion therapy, aggregates were observed in manufactured platelet products.
Preventive measures were developed during the manufacturing process to limit the formation of these
aggregates. Dr. Dana Devine and our supply chain contributed to an international forum that gathered
information on the experiences of 25 blood operators with aggregates in platelet concentrates.45 This survey
provides additional information to a phenomenon for which causes remain poorly understood.
The quality of platelets declines during their short storage time. This phenomenon is known as the platelet
storage lesion, and is much studied but not yet fully understood. The platelet storage lesion affects everything
from platelet shape to the platelet’s ability to metabolize and involves changes in the platelet’s proteins.
Dr. Devine’s group explored platelet storage lesion from a new perspective. Her group focused on what happens
to proteins, and, specifically, which proteins get cut, where they get cut, and how these protein changes might
affect protein and platelet function. The study showed widespread proteolysis in platelets during storage.46, 47
Importantly, the results showed that proteolysis in stored platelets does not just shred proteins. Instead, much of
the proteolysis is tailored, that is, it specifically processes proteins that results in stable proteins that may
function differently from the original parent protein. With the advent of new technologies to reduce the risk of
bacterial contamination of platelets comes the possibility of longer storage times for platelets. For this to become
a reality, a better understanding of the platelet storage lesion is needed.
Pathogen inactivation (PI) technologies reduce or eliminate pathogens that may be present in blood products. PI
treatment may be an alternative to testing of blood for specific infectious agents and may increase safety by
destroying unknown pathogens. While PI treatment of blood products reduces infectious risks, the technology
10
may reduce platelet quality. Dr. Devine’s group investigates the changes in proteins within platelets following PI
treatment. Her group found that PI induces platelet degradation through activation of the apoptosis pathway.48
Her group also demonstrated that PI treatment of whole blood prior to buffy coat manufacturing reduces the
quality of all blood products, including platelets.49, 50 Dr. Patrick Provost (Laval University), supported through
an grant, has also observed a negative effect of PI on platelet quality. His group has shown that PI activates
platelets through the involvement of microRNAs.51 These findings can help in the development of strategies to
improve platelet quality and minimize the negative effects of PI treatment.
Understanding the relationship between reduced platelet quality resulting from PI and clinical outcomes is
essential. The international PREPAReS clinical trial will contribute to the evaluation of a PI technology
developed by Terumo BCT. In partnership with Sanquin (the Netherlands blood operator), Norwegian
investigators and Terumo BCT, Canadian Blood Services is contributing to the Canadian arm of this trial by
providing Mirasol-treated platelet products to Canadian patients enrolled in the trial. The McMaster Transfusion
Research Program, supported by the Centre, coordinates patient enrollments at five Canadian hospitals. This trial
is a first step toward licensure of this technology in Canada.
Controversies surround the use of platelets clinically. The development of rigorous clinical guidelines for the use
of platelets is therefore needed. Dr. Alan Tinmouth, from the University of Ottawa Centre for Transfusion
Research, contributed to a systematic review on the use of platelet transfusions in various clinical settings.52
Following up from this systematic review, the AABB published clinical guidelines, to which Drs. Tinmouth and
Kathryn Webert both contributed, that provided recommendations on the use of platelets. 53 The International
Collaboration for Transfusion Medicine Guidelines, led by Dr. Nadine Shehata, with funding from the Centre
for Innovation, published clinical guidelines for platelet transfusion in patients with hypoproliferative
thrombocytopenia.54
Plasma, plasma products and plasma
product replacement
Plasma is the protein-rich liquid component of
blood that supports the immune system and controls
excessive bleeding. Plasma may be directly used for
transfusion in patients, or it can be processed into
cryoprecipitate and cryosupernatant plasma. These
two plasma derivatives are enriched in different
factors needed by different patients.
Plasma is manufactured from whole blood
or apheresis collections and stored below 18°C prior to transfusion. Canadian Blood Services
distributes ~210,000 doses annually.
Dr. William Sheffield’s team advanced the understanding of plasma quality. With Drs. Heyu Ni and Ed
Pryzdial, they developed a new mouse model in which plasma transfusion reduces bleeding. Using this model,
they demonstrated that levels of fibrinogen in transfused plasma, but not coagulation factor VIII, were important
in controlling bleeding.55 These findings question the adequacy of factor VIII, mandated by Health Canada, as a
quality control measure for plasma. The team is currently investigating prothrombin complex concentrates in this
animal model and translating their findings into human in vitro clotting assays. This work could lead to a better
understanding of the key factors in plasma that are critical to its transfusion efficacy. It could also lead to more
appropriate standards for plasma quality.
Dr. Sheffield used another mouse model to test a novel antidote to a new drug increasingly used by Canadian
patients to protect them from strokes. Called dabigatran etexilate, this drug is safer than older agents like
warfarin. However, there is no approved antidote; if a patient suffers bleeding side-effects, clinicians have few
options. With Dr. Donald Arnold, the team previously showed that plasma protein products like recombinant
factor VIIa, distributed by Canadian Blood Services, were not effective in reversing bleeding caused by
dabigatran etexilate in mice. The new antidote, a recombinant inactive clotting factor produced in the Sheffield
laboratory, was fully effective at reversing drug effects in the test tube and partially effective in reversing drug
effects in mice.56 This work could improve the effectiveness of this potential antidote and reduce wastage of
plasma protein products that are not effective in reversing dabigatran.
11
Dr. Ni also made a new fundamental contribution to scientific understanding of how plasma proteins and
platelets work together to stop bleeding. Using both genetically engineered mice and mice treated with bloodthinning drugs, his team showed that a plasma protein called fibronectin plays an important role in stitching
platelets together at the site of a blood vessel injury to stop bleeding.57 The same effect was seen in human
plasma. This work could lead to the development of a new plasma protein product and to new insights into the
optimal timing of platelet and plasma transfusions to patients in need.
Plasma can be pooled and fractionated to provide purified and virally inactivated plasma protein products, such
as albumin and intravenous immunoglobulin (IVIg). Clinical demand for IVIg rises every year. Through its
Centre for Innovation, Canadian Blood Services is working to improve the evidence base both for plasma
transfusion and for IVIg utilization and replacement to ensure the best use of the national resource of donated
plasma.
Drs. Don Branch and Alan Lazarus, working with Australian and Swiss collaborators, published a study that
countered previous paradigms for the mechanism of IVIg. In a murine model of arthritis, they confirmed the
therapeutic benefit of IVIg and IgG Fc in antibody-induced arthritis, but failed to support the significance of
sialylation and basophil involvement in the mechanism of action of IVIg therapy.58 Another study by Dr. Branch
showed that the mechanism of IVIg, at least in part, may be due to its ability to induce high levels of interleukin11 (IL-11) and that IL-11 can reduce IL-17 production, resulting in the amelioration of disease in a mouse model
of multiple sclerosis.59 This work is consistent with a role for IL-11 in IVIg mechanism. It suggests a role for
recombinant IL-11, which is commercially available, as a potential replacement of IVIg.
Dr. Lazarus is also developing safe substitutes for IVIg. His laboratory has developed CD44 antibodies and has
demonstrated their similarity to IVIg in that they both improve immune thrombocytopenic purpura (ITP) in an
animal model.60 In both cases, they are able to improve disease activity in a manner not requiring the inhibitory
Fc receptor. This information will allow the design of a CD44 antibody that does not have to interact with this
receptor. Dr. Branch is also continuing his efforts to develop IVIg substitutes. In collaboration with Dr. Lakshmi
Kotra (University of Toronto), Dr. Branch has identified a class of compounds called pyrazoles that are potent
inhibitors of phagocytosis in vitro and in vivo.61 His group is now screening additional similar compounds with
improved potency and solubility. IVIg only works in ITP but not in other diseases that involve phagocytosis.
These new drugs have the potential to not only replace IVIg in the treatment of ITP, but also in other diseases
where phagocytosis is implicated, such as rheumatoid arthritis and immune hemolytic anemias.
Anti-D is a product derived from pooled donor plasma. In the case of hemolytic disease of the fetus and newborn
(HDFN), the prophylactic use of anti-D has been highly successful in preventing immunization of the mother to
the D antigen on fetal red blood cells. Because of its limited supply, and the presence of other antibodies that can
cause problems, many attempts have been made to make anti-D in vitro. However, a successful monoclonal antiD has not yet been approved for human use. Dr. Lazarus tested various monoclonal antibodies in a murine
model to provide insight into the mechanism of action of these antibodies and further the design of monoclonal
antibodies to replace donor-derived anti-D in the prevention of HDFN.62 This paper was highlighted as being
among the top 10 per cent of papers published in the Journal of Immunology.
Hematopoietic stem cells
Hematopoietic stem cells (HSCs) are cells that can
Hematopoietic stem cells are
renew themselves and differentiate into the various
manufactured from peripheral blood or cord
mature blood cells. HSCs have been used in clinical
blood collections and stored in liquid
practice since the 1960s to treat numerous
nitrogen prior transplantation.
malignant or non-malignant blood disorders.
Canadian Blood Services manages a registry of
adult HSC donors, the OneMatch Stem Cell and
Marrow Network. Canadian Blood Services also provides autologous HSC collection, manufacturing and storage
services to a few hospitals. In 2013, Canadian Blood Services launched the national public cord blood bank.
Through the activities of the national public cord blood bank, Canadian Blood Services collects, processes and
12
stores cord blood units for use by Canadian and international patients.
In 2014, Canadian Blood Services reviewed its strategy for its HSC programs. Contributing significantly to this
review was the work performed by Ken McTaggart and Dr. John Blake from the product and process
development group. Dr. Blake’s process engineering expertise was leveraged to develop a series of mathematical
models to characterize Canadian transplant patients and HSC donors. The models identified an optimal ethnic
composition for the Canadian adult stem cell registry (OneMatch) and determined optimal recruiting targets for
adult donors. Recommendations were instrumental in the development of Canadian Blood Services' refreshed
stem cell strategy.63
Similar to blood products, autologous and cord blood HSC products must be tested for bacterial pathogens prior
to transplantation in patients. Dr. Sandra Ramirez-Arcos, our microbiologist expert, worked closely with our
stem cells manufacturing facility to validate a microbial culture system. In 2014, the results of their cord blood
study were published to inform others in the industry.64 They continue to collaborate to understand the impact of
the presence of antibiotics in cord blood on the detection of pathogens and on patient outcomes.
The product and process development group is establishing a Stem Cell Quality Monitoring Program (QMP).
Similar to its blood counterpart, this new QMP will provide in-house knowledge of stem cell products. In 20142015, initial work has focused on acquiring equipment and identifying flow cytometry-based quality assays to
evaluate stem cell viability in pre- and post-thaw cord blood samples.
Canadian Blood Services used Pentaspan in the manufacturing of its autologous and cord blood stem cell
products. However, with the market removal of Pentaspan in 2014, we needed to implement a new process for
red cell depletion of cord blood stem cell samples and for cryopreservation of autologous stem cell samples. As
part of this extensive operational process change, Dr. Jason Acker provided scientific support to ensure the
efficacy and safety of introducing Hespan as a replacement for Pentaspan.65
Stem cell transplantation from cord blood is associated with slow cell engraftment leading to long delays in the
recovery of mature blood cells, such as platelets. As a result, patients transplanted with stem cells from cord
blood require more blood transfusions and may have an extended hospital stay. Recent trials have shown that the
expansion of stem cells from cord blood before transplantation could accelerate recovery of mature blood cells.
However, recovery of platelets remains problematic. Dr. Nicolas Pineault, in collaboration with Héma-Québec,
identified novel culture conditions that efficiently improved the expansion of HSCs in vitro and enhanced their
response to a low-platelet environment in a murine model.66 Dr. Pineault is investigating the molecular
mechanisms responsible for this effect. Improving stem cell transplantation from umbilical cord blood would
lead to better patient outcomes by reducing patients' dependency on blood transfusion and limiting their
hospitalization.
Organ and tissue transplantation
The Centre for Innovation, in consultation with Canadian Blood Services' organ and tissue donation and
transplantation group, supports research that furthers our knowledge in this area.
The Centre contributes some funding to the Canadian National Transplant Research Program led by Dr. Lori
West (University of Alberta). This national initiative is designed to increase organ and tissue donation in Canada,
improve survival rates of Canadians who receive transplants and enhance their quality of life.
Through its James Kreppner Fellowship program, Canadian Blood Services supported Jennifer Chandler
(University of Ottawa) to explore an ethical and legal framework for Canada’s organ donation system. She
conducted a study to identify the emerging neuroscientific research in brain injury and its possible impact on
public attitudes to brain death and organ donation. Chandler also examined the state of knowledge on the topic of
how to ask families to consent to donation of the organs and tissue of their deceased loved ones. This study
informed decisions by Canadian Blood Services' organ and tissue team.67 She is now contributing her expertise
in health law and ethics to tackling some of the issues faced in this area. She co-leads the Ethical, Economical,
Legal and Social Platform of the Canadian National Transplant Research Program. Recently, she was honoured
13
with the Bertram Loeb Research Chair in Organ and Tissue Donation at the University of Ottawa.
Also through its James Kreppner Fellowship program, Canadian Blood Services recently granted an award to
Meaghan Toews to identify and evaluate legal and policy strategies to increase organ donation in Alberta. Most
recently, she examined the “family veto” issue and published an op-ed in the Edmonton Journal.68 “Family veto”
refers to the opportunity given to families to override their loved ones’ consent to donate and contributes to the
poor rate of organ donation in Alberta and elsewhere. Toews currently works closely with the Canadian National
Transplant Research Program network and, like Chandler, has developed ties with Canadian Blood Services'
organs and tissues team. Both researchers participate in the Donation Legal Research and Health Policy Group
facilitated by Canadian Blood Services.
Building capacity in transfusion and
transplantation
An important role for Canadian Blood Services'
Centre for Innovation is to build long-term capacity
in the field of transfusion and transplantation
sciences and medicine. To do this, the Centre
focuses on three main areas:
 salary support through competitive training
award programs
 education and training through knowledge
dissemination initiatives
 networking opportunities
Salary support
Through the Centre, Canadian Blood Services
administers four training award programs to attract
professionals to the field by providing salary
support. These training programs are designed to
attract professionals who are at various stages of
their research careers, from undergraduate to new
investigator.
Salary
support
Networking
Education
and
Training
Capacity building in transfusion
and transplantation sciences and
medicine
Figure 2: Focused areas in building long-term capacity
In the 2014–2015 fiscal year, we granted 17 new awards and renewed four (Fig. 3). All professionals receiving
our training awards are affiliated with one of the research intensive Canadian academic institutions, where, for
example, the graduate students are working toward a PhD. While most of them complete their training research
project under the mentorship of a Canadian Blood Services scientist or adjunct scientist, six are currently
conducting their training with an external group or as independent researchers (in the case of New Investigator
program awardees). Through these programs, the Centre extends its research capacity by supporting external
laboratories with a research focus that is aligned with the organization’s mandate. When possible and
appropriate, the Centre seeks partnerships to administer these programs. For example, the New Investigator
program is administered in partnership with the Canadian Institutes for Health Research.
In addition to administering its own training programs, the Centre for Innovation, through its Program Support
Award, contributes to the Centre for Blood Research (University of British Columbia) training programs. With
its research focus on transfusion medicine and blood-related diseases, the Centre for Blood Research is ideally
aligned with the mandate of the Centre for Innovation. In 2014–2015, with support from the Centre for
Innovation and other partners, the Centre for Blood Research supported 30 students from the University of
British Columbia conducting research in 15 Centre for Blood Research laboratories (Fig. 3).
In collaboration with Canadian Blood Services medical directors, the Centre for Innovation facilitates the
14
training of transfusion medicine specialists by supporting medical fellows who are enrolled in one of the five
Transfusion Medicine Diploma Programs. These medical school-based Diploma Programs are accredited by the
Royal College of Physicians and Surgeons of Canada and they are delivered in partnership with Canadian Blood
Services medical directors. In 2014–2015, Canadian Blood Services awarded one new Transfusion Medicine
Residency Fellowship to a fellow who is completing his Transfusion Medicine Diploma at McMaster University
and renewed one for a fellow also at McMaster University. Also for the first time since the inception of this
program, a fellow from Laval University in Québec received a fellowship from Héma-Québec to complete her
Diploma at the University of Toronto. This new collaboration with Héma-Québec will strengthen the national
impact of this program.
Figure 3: Number of training awards and completed degrees in 2014–2015
Program
New
Ongoing
(including renewals)
Completed training
Centre for Innovation training programs
Summer internship
8
n/a
8 internships
Graduate fellowship
4
15
2 graduate fellowships
Post-doctoral fellowship
4
6
4 post-doctoral fellowships
New Investigator program
1
1
0
Centre for Blood Research training programs
Summer internship
20
n/a
Not recorded by the Centre
Graduate fellowship
6
3
Post-doctoral fellowship
0
1
1
0
Transfusion Medicine Diploma program
Transfusion medicine
residency fellowship
1
While the number of training programs and awards distributed indicates the Centre’s success in administering
relevant programs and in engaging trainees, it does not demonstrate the impact of the programs in building
capacity. To this end, the Centre for Innovation recently reviewed its training programs and found good evidence
for such impact.
From 2000 to 2013, the Centre's training programs supported 71 graduate students leading to the completion of
10 MSc and 38 PhD degrees, 33 post-doctoral fellows and five new investigators. A number of these trainees
have since secured positions in areas related to transfusion or transplantation science and medicine in academia,
health care, not-for-profit organizations, industry, at Canadian Blood Services or Health Canada (Fig. 4).
Education and training
The Centre for Innovation also builds capacity in transfusion and transplantation science and medicine through
education and training initiatives. These initiatives are designed to share knowledge and influence practice within
and across various stakeholder communities such as researchers, health-care providers (e.g., physicians, nurses,
and medical laboratory technicians), industry representatives, regulators, and Canadian Blood Services staff.
Education and training initiatives include a transfusion medicine education website, as well as the delivery of
education events, including conferences, symposiums, workshops and seminars.
15
16
Figure 4: Examples of positions currently held by previously funded trainees (excluding transfusion medicine
fellows)
Academia
Assistant Professor, various universities
Associate Professor, University of British Columbia
Program Director, Ottawa Hospital Research Institute
Scientist, Toronto General Research Institute
Health care
Program Analyst, The Ottawa Hospital Blood & Marrow Transplant Program
Canadian Blood Services
Lab Technician, Centre for Innovation
Search Analyst, OneMatch Stem Cell and Marrow Network
Research Studies Coordinator, Epidemiology and Surveillance
Health Canada
Scientific Officer, Bureau of Cardiology, Allergy, and Neurological Sciences
Canadian Industry
Product Marketing Manager, STEMCELL technologies
Education website
The Centre manages www.transfusionmedicine.ca, an education website for health-care professionals involved in
the transfusion of blood products. The site provides original educational resources and links to reliable resources
developed by other organizations. In the last year, the site's pages were viewed more than 150,000 times (unique
page views) by more than 50,000 unique visitors.
The Clinical Guide to Transfusion is the most downloaded resource on the website with approximately 12,600
downloads in the last year (compared with 9,100 the previous year). Written in collaboration with Canadian
Blood Services medical directors and Canadian experts, and co-edited by Drs. Gwen Clarke and Sophie
Chargé, this 18-chapter guide provides a practical summary of our current knowledge of blood components and
transfusion medicine practices. Two chapters were updated last year. 69, 70 The guide is published in English and
French.
Another unique resource available on www.transfusionmedicine.ca is the Adverse Reaction Report prepared
annually by Dr. Dale Young. This report provides information about the number and type of transfusion adverse
reactions reported to Canadian Blood Services (~630 downloads in 2014–2015). Complementing the Adverse
Reaction Report, the Centre for Innovation developed A Guide to Reporting Adverse Transfusion Events. This
guide was revised during the year (~565 downloads in 2014–2015).
Original articles are also published regularly. The following articles were published in the last year:
 "Phenotype Matching for Sickle Cell Patients: A Review and Recommendations for Transfusion Practice"
17

by Drs. Robert Skeate and Mindy Goldman71 (~200 downloads in 2014–2015)
eight ResearchUnits10, 35, 44, 47, 50, 72-74; these provide clear summaries of results and impacts of research
conducted at Canadian Blood Services (~2,000 downloads in 2014–2015). Written by Canadian Blood
Services’ researchers in collaboration with the Knowledge Mobilization group, these summaries help in
further disseminating research findings to facilitate informed decision-making.75
Education events
In 2014–2015, the Centre for Innovation delivered, on its own or in partnership, 81 education events. These
events attracted an estimated 7,000 professionals (Fig. 5).
One of the key events is the Canadian Blood Services Annual International Symposium. This year’s theme was
“Plasma: Transfuse It, Fractionate It, or Forget It?” Co-chaired by Drs. William Sheffield and Kathryn Webert,
the symposium updated physicians, technologists, nurses and researchers on current knowledge in this complex
and sometimes controversial field. Delivered by international and national experts, the program aimed to:
 Improve clinical utilization of plasma, plasma protein products and recombinant proteins.
 Improve understanding of the coagulation process and how new plasma proteins and recombinants may
potentially increase safety and efficacy.
 Improve understanding of methodologies available in the clinical coagulation laboratory.
A panel discussion on the future of plasma transfusion highlighted the need for better evidence upon which to
base clinical practice. This Continuing Medical Education accredited event was well-received by attendees, and
the majority (98%) agreed that the event enhanced their knowledge in a manner that was applicable to their work
or practice. To further disseminate the knowledge shared at this live event, the presentations are available on
www.transfusionmedicine.ca. A symposium report was also published in Transfusion Medicine Reviews.76
In 2014, the Centre had the opportunity, with the leadership of Dr. Donald Branch, to co-organize and sponsor
the Red Cell Club Meeting. For the second time in its 67-year history, this prestigious knowledge exchange event
was held outside the United States. The two-day meeting brought together approximately 75 international and
national attendees representing the clinician, scientist, and trainee communities. Session topics included the
production of red blood cells, red cell membrane proteins, red cell diseases and red cell antigens. The small and
focused format of this event was very conducive to knowledge exchange and to the establishment of
collaborative efforts.
Through the Program Support Award to the Centre for Blood Research and through the activities of the Canadian
Blood Services scientists located at the Centre for Blood Research, the Centre for Innovation contributes to the
Annual Norman Bethune Symposium, the Earl W. Davie Symposium, and the Centre for Blood Research
Seminar Series. This year, the Norman Bethune Symposium provided insights into future therapies for
hemophilia and bleeding disorders and into the mechanisms of action and use of intravenous and subcutaneous
immunoglobulin therapies. The Earl W. Davie Symposium primarily focused on the coagulation pathway, and
old and new drugs affecting this pathway. While attendance at these events reached close to 160 attendees, the
Centre for Blood Research also broadcasted live and archived videos on its website.
With the leadership of Canadian Blood Services medical directors, the Centre for Innovation has established key
partnerships with provincial blood coordinating offices to deliver educational events to health-care professionals
across Canada. Again this year, Dr. Peter Lesley, co-organized with the Ontario Regional Blood Coordinating
Network the Northern and Eastern Ontario Annual Transfusion Medicine Education Videoconference
Symposium. In its ninth edition, the 2014 program focused on “Bleeding Issues in the Anti-coagulated Patient.”
The Centre also supported the 5th Annual Blood Matters Conference, organized by the Nova Scotia Provincial
Blood Coordinating Program, and the Vein to Vein Workshop, organized by the Alberta Vein to Vein Society.
These events are targeted primarily at health-care professionals working in Canadian hospitals and involved in
the transfusion of blood products. The events are essential for their continued learning and development as they
highlight new practices and guidelines and provide access to experts, which may not be available in smaller
hospitals.
18
Figure 5: Key education events organized by the Centre or delivered in partnership in 2014–2015
Event (Location)
Primary partner
Number of
attendees
Audience
Events led by the Centre for Innovation
Annual International
Symposium (Toronto)
n/a
170
Health-care providers, researchers,
industry representatives, Canadian
Blood Services staff
“Knowledge to Munch On” lunch
and learn webinar series – three
events (webinars)
n/a
109, 145, 195
Canadian Blood Services staff and
volunteers, American Red Cross
staff, Health Canada staff
LearnTransfusion Series – 29
events (webinars)
medical directors
50 per event
Health-care professionals
(physicians, technologists)
Centre for Blood
Research
160
Researchers, health-care providers, basic
science and clinical trainees, members of
the public, industry representatives,
Canadian Blood Services staff
160
Researchers, health-care providers,
basic science and clinical trainees,
members of the public, industry
representatives, Canadian Blood
Services staff
80–140 per event
Researchers, clinicians, basic
science and clinical trainees,
technicians and technologists,
industry representatives
80–140 per event
science and clinical trainees,
technicians and technologists,
industry representatives
Events delivered in partnership
Annual Norman Bethune
Symposium (Vancouver,
broadcast)
Earl W. Davie Symposium
(Vancouver, broadcast)
Centre for Blood
Research
Centre for Blood Research
weekly seminar series — 27
events (Vancouver)
Centre for Blood
Research
Centre for Blood Research
summer seminar series —
seven events (Vancouver)
Centre for Blood
Research
9th Annual Transfusion
Medicine Symposium (North
Bay, broadcast)
Ontario Regional Blood
Coordinating Network
840
Health-care providers primarily in
northern and eastern Ontario
(physicians, nurses, technologists),
Vein to Vein Workshop 2015
(Edmonton)
Alberta Vein to Vein
Society
100
Researchers, health-care providers
(physicians, nurses, technologists),
5th Annual Blood Matters
Conference (Halifax, broadcast)
Nova Scotia Provincial
Blood Coordinating
Program
100
Health-care providers (physicians,
nurses, technologists), Canadian
Red Cell Club Meeting
(Toronto)
University of Toronto
75
science and clinical trainees
Canadian Society for
Transfusion Medicine Annual
Meeting (Quebec)
Canadian Society for
Transfusion Medicine
516
Researchers, health-care providers,
basic science and clinical trainees,
industry representatives, Canadian
AABB Education Workshop —
two events (Philadelphia)
AABB
254, 150
Physicians, scientists, technologists,
managers and supervisors, CEOs
and CFOs
19
Canadian Blood Services leverages national and international events to educate the community. Every year, the
Centre contributes financially to the Canadian Society for Transfusion Medicine Annual Meeting and, in
collaboration with Héma-Québec, develops the scientific and workshop programs. This event is Canada’s
premier knowledge exchange event for the transfusion medicine community. In 2014, Drs. Sheffield, Nicolas
Pineault and Mindy Goldman were members of the scientific committee that identified topics of importance.
Dr. Goldman led a morning workshop on serology.
The Centre for Innovation also organized two education sessions at the 2014 AABB annual meeting in
Philadelphia. The first session, led by Judie Leach Bennett, entitled “Risk-based Decision-Making for Blood
Safety,” focused on the risk framework under development by an international Alliance of Blood Operators
collaboration. This initial workshop, targeted at physicians, managers and supervisors, and CEOs and CFOs, was
designed to provide attendees with an understanding of the concepts underpinning the framework, such as blood
safety risk assessment, stakeholder engagement, and health economics and outcome methods for the blood safety
decision-making process.” The second session, led by Dr. Sandra Ramirez-Arcos and moderated by Dr. Jason
Acker, entitled “Let’s Talk About the 30-Minute Rule for Red Cells,” was designed to educate attendees about
the regulatory requirements for red cell storage and transportation, to review principles of red cell quality and
storage lesion, and to disseminate the findings from Drs. Ramirez and Acker’s research projects around the 30minute rule for red blood cells. Targeted at physicians, scientists, technologists, managers and supervisors, this
education session equipped attendees with the knowledge they need to make decisions on the merits of retaining,
modifying or extending the 30-minute rule, which currently leads to unnecessary discards of red blood cells.
Finally, Dr. Branch received the 2014 Sally Frank Memorial Award and Lectureship from the AABB and
presented the named lecture at the 2014 AABB Annual Meeting. His lecture provided a detailed account of the
monocyte-macrophage assay he developed as a medical laboratory technologist and how it influenced the field of
immunohematology. Several other Canadian Blood Services experts also gave invited lectures at this annual
international meeting.
The Centre for Innovation administers the BloodTechNet competition to fund innovative projects aimed at
delivering educational resources that support the development of skills, knowledge, and expertise of health
professionals in the transfusion, transplantation and cell therapy community. Three projects were funded in 2014
and are ongoing. Dr. Christopher Ward’s team, from the University of Alberta, is developing a self-directed, selfpaced online learning module for participants to explore transfusion-related issues from bench to bedside using
an interprofessional approach. Mrs. O’Reilly’s team, from the Children’s & Women’s Health Centre of British
Columbia, is creating educational resources for health-care providers specific to blood transfusion in neonatal
and pediatric patients. The resources will include an e-learning course and a safe blood product ordering tool.
Mrs. Kenny, from the Winnipeg Regional Health Authority, is developing "snippets" to support professionals
with critical information in the moment of need, thus supporting these professionals beyond the classroom or
eLearning module setting. Finally, the Nova Scotia Provincial Blood Coordinating Program, received a
BloodTechNet award to broadcast the 2014 Blood Matters Conference.
Internally, the Centre for Innovation continues to provide educational opportunities to Canadian Blood Services'
staff across the organization by holding "lunch and learn" webinars. These events showcase presentations by
Canadian Blood Services' research groups and highlight the impact of ongoing research projects on the blood
system and operators. In its third year, the program receives positive feedback from attendees and has now been
opened to our colleagues at the American Red Cross and Health Canada, and to Canadian Blood Services
volunteers.
Networking opportunities
Promoting networking between professionals is an essential component of a strategy aimed at building capacity,
in particular to retain junior professionals to a specific field of expertise. In addition to the many educational
events described above, which promote networking, the Centre for Innovation undertakes activities specifically
aimed at enhancing the networking opportunities for junior professionals.
In 2014, the Centre for Innovation Research Day was opened to trainees and professionals working within the
20
laboratories of the Centre's core investigators. Twelve trainees attended this two-day event to discuss, with
investigators and the management team, key research projects and blood operators’ operating issues. Such faceto-face events are essential when considering the dispersed geographical locations of our research laboratories,
which span from Vancouver to Halifax. Over the coming year, the Centre for Innovation will leverage existing
networking opportunities, such as the monthly Canadian Blood Services scientific calls, to further engage junior
professionals within our internal network.
Externally, through its training programs, the Centre for Innovation provides travel funds to its graduate and
post-doctoral fellows to attend and present at national and international conferences. Trainees working within the
laboratories of Canadian Blood Services investigators are also encouraged to present at conferences where they
have the opportunity to develop collaborations.
Leveraging expertise through collaborations
The Centre for Innovation leverages internal expertise and the knowledge of the external stakeholder community
through formal and informal collaborative activities. In the last year, 31 formal partnerships were established or
renewed. This network approach allows the Centre to access external expertise, promotes the engagement of
stakeholders, and ultimately facilitates the translation of the knowledge created and provides access to additional
funding.
Research and Education Network
The Centre includes 11 permanent Canadian Blood Services research laboratories. The Centre also engages
closely with the 28 Canadian Blood Services medical directors and an epidemiologist in the delivery of research
and education activities. While these groups constitute the central node of the Centre’s research and education
network, they are connected to the larger Canadian research community through the cross-appointments of the
majority of them to Canadian academic institutions.
Complementing this central node are Canadian Blood Services adjunct scientists and Canadian research groups
that receive funding from the Centre through the competitive research and training programs. Twenty-seven
external principal investigators from across Canada were engaged during the last year.
Through netCAD, the Centre’s research development facility in Vancouver, and the Cord Blood for Research
program, the Centre engages with numerous Canadian research groups by providing blood and cord blood
research products. Working closely with Canadian Blood Services’ Cord Blood Bank, the Centre implemented
the Cord Blood for Research program in August 2014 to facilitate the distribution of unbankable fresh cord blood
units to researchers across Canada. The program has been well received by the community, who until now had
difficulties in accessing high-quality and ethically procured cord blood for their research projects. In 2014–2015,
these unique programs distributed 976 research products (810 whole blood, 119 apheresis platelet products,
47 cord blood units) to 36 research projects (16 internal and 20 external to the Centre) from across Canada.77
At an international level, the Centre’s researchers continue to build strong collaborative research projects
primarily through their memberships in the Biomedical Excellence for Safer Transfusion Collaborative (BEST).
In the last year, Centre researchers contributed to several BEST studies. The Centre also continues to undertake
contract research for various industry partners including Terumo BCT Inc., Armour Therapeutics,
Immunobiochem Corporation, and CSL Behring AG. These arrangements provide substantive research support
to further technology and biologics development for the future benefit of the blood system.
In the realm of education, the Centre partners with numerous local, provincial and national organizations, as
described in the previous section (Fig. 5).
Canadian Blood Utilization Collaborative
Upon the request of the Conference of Deputy Ministers of Health, Canadian Blood Services submitted a
Proposal for the Utilization of Blood and Blood Products in March 2014. In the proposal, Canadian Blood
21
Services identified opportunities to improve the national
utilization of blood products to improve patient
outcomes and to reduce overall system costs. One of the
initiatives included in the proposal was a forum through
which blood utilization research and clinical program
proposals could be discussed, reviewed and prioritized,
along with strategies to collect relevant data and
evidence, and through which diversified funding
sources for such initiatives could be pursued. Taking a
system-wide approach, the proposed forum was
conceived to inform clinical practice, policy-making,
and health-care investment decisions in the domain of
blood utilization.
Figure 6: Stakeholder engagement in the Canadian
Blood Utilization Collaborative
Health-care professionals
(physicians, nurses, transfusion safety officers)
Clinical investigators
Scientists
Health administrators
Blood operators
Funders
Over the last year, members of the Centre for
Innovation worked with Canadian Blood Services'
utilization group led by Dr. Kathryn Webert to bring together a group of 35 thought leaders from across Canada
(Fig. 6). An initial meeting, held in Toronto in early 2015, was organized to enable the participants to describe
the current state of blood utilization in Canada, articulate blood utilization objectives for the future and develop a
mechanism to enable collective action on these objectives. There was a consensus that there was a need "to
optimize blood utilization to improve patient outcomes in a cost-effective manner" and that this work was best
accomplished collectively. Work is underway to establish a governance structure that will facilitate the activities
of the collaborative while leveraging participants' expertise.
International Collaboration for Transfusion Medicine Guidelines
The Centre for Innovation continues to support Dr. Nadine Shehata in her leadership role in the International
Collaboration for Transfusion Medicine Guidelines (ICTMG) group. In 2014, the group published new platelet
transfusion guidelines to assist health-care professionals in optimizing platelet utilization during the treatment of
chemotherapy or stem cell transplant patients.54 This publication was highlighted in Transfusion News. The
group is now working on guidelines for the management of fetal and neonatal alloimmune thrombocytopenia.
This disorder is characterized by low platelet count in fetuses and newborns, which can cause severe
complications and long-term disabilities. Guidelines are also being developed for red cell specifications for
patients with hemoglobinopathies, genetic defects affecting red blood cells.
Alliance of Blood Operators
Figure 7: ABO members
Since 2014, the Centre for Innovation has been
Canadian Blood Services’ point of contact for our
collaboration with the Alliance of Blood Operators. The NHS Blood and Transplant (U.K.)
Alliance is a network of not-for-profit blood service
Australian Red Cross Blood Services
providers with voluntary, non-remunerated blood
donors (Fig. 7). One of the goals of the Alliance of
America’s Blood Centers
Blood Operators is to facilitate horizontal learning
across its membership to identify and promote good
American Red Cross
practice and performance improvement. The
confidentiality agreement binding these organizations
Blood Systems Inc. (U.S.)
ensures the dissemination of valuable information. In
European Blood Alliance
the last year, Canadian Blood Services participated in
66 knowledge exchanges. Thirty-three of these
exchanges were initiated by our organization to learn
from these international members’ best practices in
various areas (e.g., look-back/trace-back processes, quality management system workflows, National Contact
Centre operations).
22
One of these activities focused on the look-back and trace-back processes implemented by blood operators to
ensure product safety. Despite strict screening procedures and highly effective testing, there is the potential, in
rare instances, for an infected unit of blood to be released for transfusion. A trace-back begins with a patient who
may have a transfusion-related infection. A targeted search to identify which donor(s) gave that person blood is
conducted. A look-back begins with an infected donor. In this case, a targeted search to identify which patients
received the donor's blood is conducted. Look-back and trace-back processes are in place to limit the potential
damage of an infected donation. In 2014, Canadian Blood Services reviewed its look-back and trace-back
processes. Through the Alliance, we obtained information from several blood operators about the scope and
limits of their programs. Many operators have made provision in their process to limit look-back procedures, and
their rationales for doing so are informing our deliberations. A review of the information confirmed the
opportunity for our organization to streamline our process, thereby achieving efficiencies without adding risk to
recipient safety.
Risk-Based Decision Making Framework
The Risk-Based Decision Making Framework project, led by Judie Leach Bennett together with the members
of an international Alliance of Blood Operators collaboration, was recently concluded. A final risk framework
was delivered, informed by stakeholder consultation, peer review, and scenario-based feasibility testing as a tool
for decision-making. A web-based, interactive version of the framework is also being developed.
Governance
In the last year, the Centre for Innovation continued to gain efficiencies and further integrate its Research,
Knowledge Mobilization, and product and process development groups. Canadian Blood Services also
established two new committees:


Product Innovation Operating Committee: This committee facilitates and directs the introduction of new products,
changes to products and their associated processes, and the retirement of obsolete products distributed by Canadian
Blood Services. Dr. Dana Devine chairs the committee and Ken McTaggart is a member.
Product Development Working Group: This working group provides ongoing advice and recommendations for minor
changes to Canadian Blood Services products or processes. Dr. Jason Acker, Craig Jenkins and Ken McTaggart are
members.
These groups will enhance the integration of the Centre for Innovation's research and development efforts with
the operations of our organization. They complement the already well-established Canadian Blood Services
governance structure, which provides oversight to the Centre’s activities. This governance structure includes the
Canadian Blood Services board of directors, the Safety, Research and Ethics Committee, the Scientific and
Research Advisory Committee, and the Research Ethics Board. These committees meet throughout the year and
are regularly apprised about the Centre’s activities.
In 2014, the Centre’ secretariat administered 12 funding competitions for our research and training programs,
which resulted in funding 29 new projects (Appendix 1). Again this year, each competition followed strict peerreview processes that promote excellence, ensure relevance and reach a broad spectrum of Canada’s leading
researchers in our field. In particular, we renewed our agreement with the Canadian Institutes for Health
Research for the Canadian Blood Services/CIHR operating grant and the New Investigator programs. Through
this agreement, Canadian Blood Services reviews the Relevance section of the applications for alignment with
the Centre’s mission, and CIHR conducts the peer-review process and provides funding recommendations. For
the intramural grant program, our management team conducts a relevance review at the Letter of Intent stage,
and we convene an external grant review panel to rank the applications and make funding recommendations. The
panel consists of international and Canadian experts, including a scientist from Héma-Québec.
In 2013, the Centre for Innovation, in collaboration with Health Canada, developed a performance measurement
strategy for the program. Implementation of this strategy provides information for the evaluation of the program
to assess relevance and performance. It is also used to support effective management and reporting requirements
of Health Canada’s contribution funding. In 2014, we refined the strategy to ensure the quality of the
performance information will support the program evaluation and reporting accountability requirements.
23
References cited
(see Appendix II for a full list of the Centre for Innovation’s publications for fiscal year 2014–
2015)
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
O'Brien SF. Surveillance Report 2014. transfusionmedicine.ca website 2015.
Fearon M, Scalia V, O'Brien S F, Bigham M, Andonov A, Weger S, Bernier F, Dubuc S, Delage G,
Germain M. Babesia and Hepatitis E Seroprevalence in Canadian Blood Donors. Can J Infect Dis Med
Microbiol 2014; 25: e38.
Fearon M, Scalia V, O'Brien S F, Bigham M, Andonov A, Weger S, Bernier F, Dubuc S, Delage G,
Germain M. Babesia and Hepatitis E Seroprevalence in Canadian Blood Donors. Canadian Society For
Transfusion Medicine Website 2014.
Fearon M, Scalia V, O’Brien S, Bigham M, Andonov A, Weger S, Bernier F, Dubuc S, Delage G,
Germain M. Seroprevalence of Babesia and Hepatitis E in Canadian Blood Donors. Transfusion 2014; 54:
27A.
O’Brien S, Delage G, Seed C, Pillonel J, Corbi C, Davison K, Kitchen A, Steele W, Leiby D. An
Assessment of Travel to Malaria Endemic Regions from Five Non-Endemic Countries. Vox Sang 2014; 107:
23.
O’Brien S, Osmond L, Goldman M. Donor Compliance with the Criterion for Men Who Have Sex with
Men (MSM) Prior to Implementation of a 5-Year Deferral. Transfusion 2014; 54: 35A-6A.
Goldman M, Lapierre D, Lemay L, Devine D, Sher G. Donor Criteria for Men Who Have Sex with Men: A
Canadian Perspective. Transfusion 2014; 54: 1887-92.
Lieberman L, Devine DV, Reesink HW, Panzer S, Wong J, Raison T, Benson S, Pink J, Leitner GC,
Horvath M, Compernolle V, Scuracchio PSP, Wendel S, Delage G, Nahirniak S, Dongfu X, Krusius T,
Juvonen E, Sainio S, Cazenave JP, Guntz P, Kientz D, Andreu G, Morel P, Seifried E, Hourfar K, Lin CK,
O'Riordan J, Raspollini E, Villa S, Rebulla P, Flanagan P, Teo D, Lam S, Ang AL, Lozano M, Sauleda S,
Cid J, Perreira A, Ekermo B, Niederhauser C, Waldvogel S, Fontana S, Desborough MJ, Pawson R, Li M,
Kamel H, Busch M, Qu L, Triulzi D. Prevention of Transfusion-Transmitted Cytomegalovirus (CMV)
Infection: Standards of Care. Vox Sang 2014; 107: 276-311.
Goldman M. Iron Status in Canadian Blood Services Donors. transfusionmedicine.ca website 2014.
Goldman M. ResearchUnit: Protecting Our Life Blood: Iron Deficiency in Canadian Blood Donors.
transfusionmedicine.ca website 2014.
Uzicanin S, O'Brien SF, Goldman M. Impact of Updated Letter for Donors with Low Hemoglobin.
Canadian Society For Transfusion Medicine Website 2014.
Removal of Cue from the Screening Process. License Amendment Notifcation to Health Canada 2014.
Mastronardi C, Acker J. Blood Packs and Platelet Pooling Set Replacement Project - Technical Summary
Report. Internal report submitted to Canadian Blood Services, Chantal Couture, Project Manager 2014.
Acker J, Yi QL. Blood Packs and Platelet Pooling Set Replacement Project - Sample Size and Testing
Specifications Pooled Platelets. Internal report submitted to Canadian Blood Services 2014.
Changes to Macopharma Whole Blood Collection Set and Introduction of the Macopharma Platelet Pooling
Set. License Amendment Notifcation to Health Canada 2014.
Discontinuation of Balancing Whole Blood Prior to Centrifugation. License Amendment Notifcation to
Health Canada 2013.
Ramirez-Arcos S. Evaluation of Alternative Skin Disinfection Methods for Donors Allergic to
Chlorhexidine. Internal report submitted to Canadian Blood Services, Mindy Goldman, Medical Director,
Donor and Clinical Services 2014.
Lacroix J, Hebert PC, Fergusson DA, Tinmouth A, Cook DJ, Marshall JC, Clayton L, McIntyre L, Callum
J, Turgeon AF, Blajchman MA, Walsh TS, Stanworth SJ, Campbell H, Capellier G, Tiberghien P, Bardiaux
L, van de Watering L, van der Meer NJ, Sabri E, Vo D. Age of Transfused Blood in Critically Ill Adults. N
Engl J Med 2015; 372: 1410-8.
Heddle NM, Eikelboom J, Liu Y, Barty R, Cook RJ. Exploratory Studies on the Age of Transfused Blood
and in-Hospital Mortality in Patients with Cardiovascular Diagnoses. Transfusion 2015; 55: 364-72.
Blake J, Hardy M. Evaluating the Impact of Shorter Shelf Life for Red Blood Cells with a Generic
Simulation. Industrial and Systems Engineering Research Conference - Conference Proceedings Website
2014.
Blake J, Hardy M. Evaluating the Impact of Shorter Shelf Life for Red Blood Cells with a Generic
Simulation. Canadian Society For Transfusion Medicine Website 2014.
Hardy M. Simulation of a Reduced Red Blood Cell Shelf Life. MASc. Supervisor: Blake J. Dalhousie
University; 2015.
Blake J. On the Use of a Generic Model for Evaluating Site-to-Site Inventory Transfers. Internal report
submitted to Canadian Blood Services, Rick Trifunov, Director of Supply Chain Operations Planning 2014.
24
24. Blake JT, Hardy M. A Generic Modelling Framework to Evaluate Network Blood Management Policies:
The Canadian Blood Services Experience. Oper Res Health Care 2014; 3: 116-28.
25. Ramirez-Arcos S, Thibault L. The Effects of Room Temperature Exposure on Bacterial Growth in RBC
Units. External report submitted to Canadian Standards Association Working Group on the 30-minute rule
2014.
26. Ramirez-Arcos S. The Effects of Room Temperature Exposure on Red Blood Cell Units. Internal report
submitted to Canadian Blood Services, Supply Chain 2014.
27. Acker JP, Hansen AL, Kurach JD, Turner TR, Croteau I, Jenkins C. A Quality Monitoring Program for
Red Blood Cell Components: In Vitro Quality Indicators before and after Implementation of Semiautomated
Processing. Transfusion 2014; 54: 2534-43.
28. Hansen AL, Kurach JDR, Turner TR, Jenkins C, Busch MP, Norris PJ, Dugger J, Tomasulo PA, Devine
DV, Acker JP. The Effect of Processing Method on the in Vitro Characteristics of Red Blood Cell Products.
Vox Sang 2015.
29. Chasse M, McIntyre L, Tinmouth A, Acker J, English SW, Knoll G, Forster A, Shehata N, Wilson K, van
Walraven C, Ducharme R, Fergusson DA. Clinical Effects of Blood Donor Characteristics in Transfusion
Recipients: Protocol of a Framework to Study the Blood Donor-Recipient Continuum. BMJ Open 2015; 5:
e007412.
30. Guo Q, Duffy SP, Matthews K, Santoso AT, Scott MD, Ma H. Microfluidic Analysis of Red Blood Cell
Deformability. J Biomech 2014; 47: 1767-76.
31. Myrand-Lapierre ME, Deng X, Ang RR, Matthews K, Santoso AT, Ma H. Multiplexed Fluidic Plunger
Mechanism for the Measurement of Red Blood Cell Deformability. Lab Chip 2015; 15: 159-67.
32. Schulze HG, Atkins CG, Devine DV, Blades MW, Turner RF. Fully Automated Decomposition of Raman
Spectra into Individual Pearson's Type VII Distributions Applied to Biological and Biomedical Samples.
Appl Spectrosc 2015; 69: 26-36.
33. Hysi E, Strohm EM, Berndl E, Acker J, Kolios MC. Assessing Storage-Induced Red Blood Cell Lesions
Using Photoacoustic Measurements of Oxygen Saturation and Frequency Content of Pa Signals. IEEE
International Ultrasonics Symposium Website 2014: 352.
34. Chapanian R, Kwan DH, Constantinescu I, Shaikh FA, Rossi NA, Withers SG, Kizhakkedathu JN.
Enhancement of Biological Reactions on Cell Surfaces Via Macromolecular Crowding. Nat Commun 2014;
5: 4683.
35. Scott MD. ResearchUnit: Using Immunocamouflage to Fool the Immune System. transfusionmedicine.ca
website 2015.
36. Kosan C, Rashkovan M, Ross J, Schaffer AM, Saba I, Lemsaddek W, Trudel M, Moroy T. The
Transcription Factor Miz-1 Is Required for Embryonic and Stress-Induced Erythropoiesis but Dispensable
for Adult Erythropoiesis. Am J Blood Res 2014; 4: 7-19.
37. Vassen L, Beauchemin H, Lemsaddek W, Krongold J, Trudel M, Moroy T. Growth Factor Independence 1b
(Gfi1b) Is Important for the Maturation of Erythroid Cells and the Regulation of Embryonic Globin
Expression. PLoS One 2014; 9: e96636.
38. Wang A, Kluger R. Increasing Efficiency in Protein-Protein Coupling: Subunit-Directed Acetylation and
Phase-Directed Cuaac ("Click Coupling") in the Formation of Hemoglobin Bis-Tetramers. Biochemistry
2014; 53: 6793-9.
39. Bian Y, Chang TM. A Novel Nanobiotherapeutic Poly-[Hemoglobin-Superoxide Dismutase-CatalaseCarbonic Anhydrase] with No Cardiac Toxicity for the Resuscitation of a Rat Model with 90 Minutes of
Sustained Severe Hemorrhagic Shock with Loss of 2/3 Blood Volume. Artif Cells Nanomed Biotechnol
2015; 43: 1-9.
40. Acker J, Yi Q, Hannach B. Introduction of the Acp-215 Cell Processor for Red Blood Cell Washing.
Internal technical report submitted to Canadian Blood Services 2015.
41. Ramirez-Arcos S. Certificate of Conformance - BPA and BPN Lots. Internal report submitted to Canadian
Blood Services, Quality Assurance 2014-2015.
42. Ramirez-Arcos S. Bacterial Detection Testing - Proficiency Test Kits and Proficiency Testing Results
Reports. Internal report submitted to Canadian Blood Services, Wanda Lefresne, Associate Director,
Production Process Management 2014.
43. Taha M, Kalab M, Yi QL, Landry C, Greco-Stewart V, Brassinga AK, Sifri CD, Ramirez-Arcos S.
Biofilm-Forming Skin Microflora Bacteria Are Resistant to the Bactericidal Action of Disinfectants Used
During Blood Donation. Transfusion 2014; 54: 2974-82.
44. Ramirez-Arcos S. ResearchUnit: Dodging Disinfection: Biofilm-Forming Skin Bacteria Can Resist
Disinfectants. transfusionmedicine.ca website 2014.
45. van der Meer PF, Dumont LJ, Lozano M, Bondar N, Wong J, Ismay S, Pink J, Nussbaumer W, Coene J,
Feys HB, Compernolle V, Devine DV, Howe D, Lin CK, Sun J, Ringwald J, Strasser EF, Eckstein R,
Seltsam A, Perseghin P, Proserpio P, Wakamoto S, Akino M, Takamoto S, Tadokoro K, Teo D, Shu PH,
Chua SS, Jimenez-Marco T, Lozano M, Cid J, Castro E, Muñoz I, Gulliksson H, Sandgren P, Thomas S,
25
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
Petrik J, McColl K, Kamel H, Dugger J, Sweeney JD, Gorlin JB, Sutor LJ, Heath D, Sayers MH. Aggregates
in Platelet Concentrates. Vox Sang 2015; 108: 96-100.
Prudova A, Serrano K, Eckhard U, Fortelny N, Devine DV, Overall CM. Tails N-Terminomics of Human
Platelets Reveals Pervasive Metalloproteinase-Dependent Proteolytic Processing in Storage. Blood 2014;
124: e49-60.
Serrano K. ResearchUnit: Making the Cut: Protein Breakdown in Platelets During Storage.
Chen Z, Schubert P, Culibrk B, Devine DV. P38mapk Is Involved in Apoptosis Development in Apheresis
Platelet Concentrates after Riboflavin and Ultraviolet Light Treatment. Transfusion 2014.
Schubert P, Culibrk B, Karwal S, Serrano K, Levin E, Bu D, Bhakta V, Sheffield WP, Goodrich RP,
Devine DV. Whole Blood Treated with Riboflavin and Ultraviolet Light: Quality Assessment of All Blood
Components Produced by the Buffy Coat Method. Transfusion 2014.
Schubert P. ResearchUnit: Pathogen Inactivation for Safer Blood Transfusion: What Are the Limitations?
Osman A, Hitzler WE, Meyer CU, Landry P, Corduan A, Laffont B, Boilard E, Hellstern P, Vamvakas EC,
Provost P. Effects of Pathogen Reduction Systems on Platelet Micrornas, mRNAs, Activation, and Function.
Platelets 2015; 26: 154-63.
Kumar A, Mhaskar R, Grossman BJ, Kaufman RM, Tobian AA, Kleinman S, Gernsheimer T, Tinmouth
AT, Djulbegovic B. Platelet Transfusion: A Systematic Review of the Clinical Evidence. Transfusion 2014.
Kaufman RM, Djulbegovic B, Gernsheimer T, Kleinman S, Tinmouth AT, Capocelli KE, Cipolle MD,
Cohn CS, Fung MK, Grossman BJ, Mintz PD, O'Malley BA, Sesok-Pizzini DA, Shander A, Stack GE,
Webert KE, Weinstein R, Welch BG, Whitman GJ, Wong EC, Tobian AAR. Platelet Transfusion: A
Clinical Practice Guideline from the AABB. Annals of Internal Medicine 2015; 162: 205-13.
Nahirniak S, Slichter SJ, Tanael S, Rebulla P, Pavenski K, Vassallo R, Fung M, Duquesnoy R, Saw C-L,
Stanworth S, Tinmouth A, Hume H, Ponnampalam A, Moltzan C, Berry B, Shehata N. Guidance on
Platelet Transfusion for Patients with Hypoproliferative Thrombocytopenia. Transfus Med Rev 2015; 29: 313.
Eltringham-Smith LJ, Lei X, Reheman A, Lambourne MD, Pryzdial EL, Ni H, Sheffield WP. The
Fibrinogen but Not the Factor VIII Content of Transfused Plasma Determines Its Effectiveness at Reducing
Bleeding in Coagulopathic Mice. Transfusion 2014.
Sheffield WP, Lambourne MD, Eltringham-Smith LJ, Bhakta V, Arnold DM, Crowther MA. Gt-S195a
Thrombin Reduces the Anticoagulant Effects of Dabigatran in Vitro and in Vivo. J Thromb Haemost 2014;
12: 1110-5.
Wang Y, Reheman A, Spring CM, Kalantari J, Marshall AH, Wolberg AS, Gross PL, Weitz JI, Rand ML,
Mosher DF, Freedman J, Ni H. Plasma Fibronectin Supports Hemostasis and Regulates Thrombosis. J Clin
Invest 2014; 124: 4281-93.
Campbell IK, Miescher S, Branch DR, Mott PJ, Lazarus AH, Han D, Maraskovsky E, Zuercher AW,
Neschadim A, Leontyev D, McKenzie BS, Kasermann F. Therapeutic Effect of IVIG on Inflammatory
Arthritis in Mice Is Dependent on the Fc Portion and Independent of Sialylation or Basophils. J Immunol
2014; 192: 5031-8.
Figueiredo CA, Drohomyrecky PC, McCarthy SDS, Leontyev D, Ma X-Z, Branch DR, Dunn SE. Optimal
Attenuation of Experimental Autoimmune Encephalomyelitis by Intravenous Immunoglobulin Requires an
Intact Interleukin-11 Receptor. PLoS One 2014; 9: e101947.
Crow AR, Amash A, Lazarus AH. CD44 Antibody-Mediated Amelioration of Murine Immune
Thrombocytopenia (ITP): Mouse Background Determines the Effect of Fcgammariib Genetic Disruption.
Transfusion 2014.
Purohit MK, Chakka SK, Scovell I, Neschadim A, Bello AM, Salum N, Katsman Y, Bareau MC, Branch
DR, Kotra LP. Structure-Activity Relationships of Pyrazole Derivatives as Potential Therapeutics for
Immune Thrombocytopenias. Bioorg Med Chem 2014; 22: 2739-52.
Yu H, Stowell SR, Bernardo L, Hendrickson JE, Zimring JC, Amash A, Uchikawa M, Lazarus AH.
Antibody-Mediated Immune Suppression of Erythrocyte Alloimmunization Can Occur Independently from
Red Cell Clearance or Epitope Masking in a Murine Model. J Immunol 2014; 193: 2902-10.
Blake J. Modelling the Adult and Cord Stem Cell Registries: A Potpourri of Engineering Models. Internal
report submitted to Canadian Blood Services, Donna Killeen, Director of Strategic Performance 2014.
Ramirez-Arcos S, Kou Y, Yang L, Perkins H, Taha M, Halpenny M, Elmoazzen H. Validation of Sterility
Testing of Cord Blood: Challenges and Results. Transfusion 2015.
Acker JP. HPC Apheresis Pentaspan Replacement (Phase 1) - Statistical Analysis. Internal report submitted
to Canadian Blood Services, Heidi Elmoazzen, Director, National Public Cord Blood Bank 2014.
Dumont N, Boyer L, Emond H, Saltik BC, Pasha R, Bazin R, Mantovani D, Roy DC, Pineault N. Medium
Conditioned with Mesenchymal Stromal Cell-Derived Osteoblasts Improves the Expansion and Engraftment
Properties of Cord Blood Progenitors. Exp Hematol 2014; 42: 741-52.
26
67. Chandler JA, Connors M. Effective Requesting in Organ Donation: A Review of the Literature (2000-2013).
Internal report submitted to Canadian Blood Services 2014.
68. Toews M, Caulfield T. Opinion: 'Family Veto' Dilemma and Organ Donation. Edmonton journal 2014.
69. Webert K, Hume H, Revised by Clarke G and Hannon J. Hdfn and Perinatal Immune Thrombocytopenia.
In Clinical Guide to Transfusion. Edited by Clarke G, Charge SB. Published in transfusionmedicine.ca by
Canadian Blood Services, 2015.
70. Young D. Emergency Transfusion. In Clinical Guide to Transfusion. Edited by Clarke G, Charge S.
Published in transfusionmedicine.ca by Canadian Blood Services, 2014.
71. Skeate R, Goldman M. Phenotype Matching for Sickle Cell Patients: A Review and Recommendations for
Transfusion Practice. transfusionmedicine.ca website 2014.
72. Acker JP. ResearchUnit: A Sweet Solution for Infant Transfusions? transfusionmedicine.ca website 2014.
73. Ni H. ResearchUnit: Plasma Fibronectin: Keeping the Delicate Balance between Bleeding and Clotting.
74. Semple J. ResearchUnit: Research into TRALI Therapies Gene Therapy Results That Are a Tad Interesting!
75. Chargé S, Walsh G. Bridging the Gap: Knowledge Mobilization and Transfusion Medicine Research.
Transfusion 2014; 54: 231A.
76. Zeller MP, Al-Habsi KS, Golder M, Walsh GM, Sheffield WP. Plasma and Plasma Protein Product
Transfusion: A Canadian Blood Services Centre for Innovation Symposium. Transfus Med Rev 2015.
77. Beak C, Charge SB, Isasi R, Knoppers BM. Developing Educational Resources to Advance Ethical
Umbilical Cord Blood Research: A Canadian Perspective. Canadian Society For Transfusion Medicine
Website 2014.
27
Appendix I: Funded projects
Summary of funded research projects by program
Projects receiving funding in fiscal year 2014–2015
Total: 137
Research program
51
Canadian Blood Services/CIHR Partnership Operating
Grants
27
Blood Utilization and Conservation (21)
Transfusion-Related Acute Lung Injury (2)
Blood Supply Risk (4)
Canadian Blood Services/CIHR Partnership New
Investigator Awards
2
Intramural operating grants
7
Small projects funding
4
James Kreppner Fellowships
2
Supplementary funding
9
Product and Process Development program
54
Integrated Development program
38
Development in collaboration with external agencies
13
Participation in international benchmarking studies,
technology evaluations, and knowledge exchange
activities
3
National training program
29
Canadian Blood Services/CIHR Partnership Post-Doctoral
1
Fellowships
Post-doctoral fellowships
9
Graduate fellowships
19
Program Support Award for Canadian Transfusion
Medicine and Science Research
3
i
Titles of projects funded by Research program
Note: Projects that are italicized are those for which funding was initiated in fiscal year 2014–2015.
Canadian Blood Services/CIHR Partnership National Operating Grant program
Purpose: Blood utilization and conservation
Characterization of Regulatory Interactions/Complex in Hemoglobin Switching
Hydrophilic Polymer Brushes as Biocompatible Coatings: Development and Applications in Blood
Handling and Platelet Storage
Development of a Novel Method for the Surface Engineering of Red Blood Cells Comprising Chemical and
Enzymatic Cell Surface Modification
The Ability of Plasma or Plasma Replacement Products to Control Bleeding in Over-Anticoagulated Mice
Auxiliary Cofactors in Fibrinolysis
Cold Storage of Platelets via Membrane Pegylation
The Use of Antibody-Mediated Immune Suppression as a Model in the Development of a Replacement for
RhD Prophylaxis in Haemolytic Disease of the Fetus and Newborn
Improving the Cryostorage of Blood Products Using Novel Small Molecule Cryoprotectants
Small Molecule Inhibitors of Phagocytosis as Replacement Therapy for IVIg
Development of Novel Blood Vessel and Organ Sealants for Blood Conservation in Surgical Practice
Platelet Micrornas During Storage Under Blood Bank Conditions
Transfusion of Red Cells in Hematopoietic Stem Cell Transplantation: The TRIST Study
Tranexamic Acid Versus Placebo to Reduce Perioperative Blood Transfusion in Patients Undergoing Major
Liver Resection: A Pilot Randomized Controlled Trial
Understanding Host Mechanisms Responsible for Immune Platelet Destruction and Thrombocytopenia
Polyhemoglobin Catalase Superoxide Dismutase Carbonic Anhydrase: A Novel Soluble Biotherapeutic with
No Cardiac Toxicity for Hemorrhagic Shock and Other Uses
Characterization of ohe Hematopoietic Reconstitution Enhancing Activity of Osteoblasts Derived from
Human Mesenchymal Stromal Cells
Design and Implementation of Circulatory Oxygen Therapeutics Derived from Human Hemoglobin by
Improved Systematic Chemical Coupling and Cross-Linking
Release, Delivery and Cell Programming Effects of Platelet Microparticles and Micrornas
Microfluidic Devices to Measure the Deformability of Stored Red Blood Cells
Understanding Transcriptional and Epigenetic Control by Gfi1b Towards the Development of a Therapy
for Sickle Cell Disease
Pathogenesis and Treatment of Immune Thrombocytopenia: Are There Fundamental Differences Between
Anti-GP1ba- and Anti-Gpllbllla-Mediated Thrombocytopenia?
Purpose: Transfusion-related acute lung injury
Identification of Host Immune Factors Responsible for the Initiation and/or Modulation of Transfusion
Related Acute Lung Injury
Mechanisms of Antibody-Independent Transfusion-Related Acute Lung Injury (TRALI)
Purpose: Blood supply risk
Canada's Blood Futures: Geography, Demographic Change, and the Supply and Demand of Blood in
Canada
Transfusion-Related Epstein-Barr Virus (EBV) Infection Among Allogeneic Stem Cell Transplant Pediatric
Recipients: A Multicenter Prospective Cohort Study (Treasure Study)
Short and Long-Term Clinical Effects of Blood Donor Characteristics in Transfusion Recipients
Exploratory Analyses to Determine if Method of Donor Blood Processing Affects Outcome in Transfused
Recipients
ii
Canadian Blood Services/CIHR Partnership New Investigator Program
Transfusion Requirements in Cardiac Surgery II (TRICS II)
Code Sepsis: Defining and Translating Optimal Resuscitation and Care for Children with Septic Shock
Intramural Operating Grant Program
Quality of Transfusable Plasma: Mouse Models and Clinical Samples
Stealth Erythrocytes: From Bench to Bedside
Mechanism of Action of Intravenous Immunoglobulin (IVIg): Role of Dendritic Cells in Stimulating T
Regulatory Cells
Antibodies to CD44 as a Potential Replacement for IVIg in ITP
Residual Risk of Transfusion-Transmitted Cytomegalovirus Infection: Incidence and Pathogenesis
Defining the Components of Transfusable Plasma That Reduce Bleeding
Elucidation of the Mechanism of IVIg-Associated Hemolysis
Small Projects program
Use of Platelet Transfusions in Medical-Surgical Critically Ill Patients
Trends and Predictors of Transfusion in Obstetrical Patients
Understanding Brain Death: A Multipurpose Educational Video Aimed to a Diverse Public and
Professional Audience
Retrospective Analysis of Clinical Outcomes in Neonatal Alloimmune Thrombocytopenia (NAIT) Related
to Anti-HPA-1a
James Kreppner Fellowship in Blood System Studies
A Framework for Thinking Through Different Concepts of Death in Organ Donation and
Transplantation
Legal and Policy Strategies to Optimize Organ Donation in Alberta
Supplementary Funding Program
Purpose: External grant top-up
CIHR: Polymer-Grafted Allogenic Leukocytes and Systemic Immune Modulation
Heart & Stroke Foundation: Auxiliary Cofactors in Fibrinolysis
Burroughs Wellcome Fund: Innovation in Regulatory Science
CIHR: Pathogenesis and Treatment of Immune Thrombocytopenia: Are There Fundamental
Differences Between Anti-Gpibα- and Anti-Gpllbllla-Mediated Thrombocytopenia?
Heart & Stroke Foundation: Apolipoprotein A-IV and Platelet Function: Novel Links with Thrombosis,
Inflammation, and Atherosclerosis
CIHR: Pathogenesis of Fetal and Neonatal Alloimmune Thrombocytopenia and IVIg Anti-Fcrn
Therapies
Purpose: Bridge funding
Small Molecule Inhibitors of Phagocytosis as Replacement Therapy for IVIg
Impact of Cord Blood Processing Delay on the Loss of Engraftment Activity and on the Release of
Microparticles
Understanding the Physiological Mechanisms Responsible for the Predominance of Staphylococcus
Epidermidis as a Platelet Contaminant — A Genomic Approach
iii
Titles of projects funded by Product and Process Development program
Integrated Development program
Exploration of Options to Test Cord Blood Units That Contain Antibiotics for Bacterial Contamination
Product Characterization — Quality Monitoring Program for Cord Blood Derived Hematopoietic Stem
Cells
Elimination of Cooling Trays
Acp-215 Closed System Cryopreservation
Non-Destructive Quality Control Testing Technique for Apheresis Products
Pentastarch Replacement Cord Blood Manufacturing
Hematopoietic Progenitor Cells Apheresis Pentaspan Replacement
Bag RFP Project
Evaluation of Alternative Skin Disinfection Kits for Donors Allergic to Chlorhexidine
The Effects of Room Temperature Exposure on Red Blood Cell Units (30-Minute Rule)
In-House Sterility Testing of Cord Blood Units
Site Inventory Model and Analysis
Paperless Clinic: Whole Blood Clinic Staffing Planning Templates
OneMatch Registry Study
Stem Cell International Benchmarking
Product Characterization — Quality Monitoring Program Database
Production Equipment Process Cycle Time Optimization: Compomat
Current State of 7-Day Platelets Whitepaper
Current State of Platelet Additive Solutions Whitepaper
Paperless Clinic: Plasma Apheresis Clinic Staffing Planning Templates
Hospital Ordering Behaviour and Management of O- Inventory
Modelling and Simulation Education and Training
Investigation of the Bactericidal Effect of the Buffy Coat Platelet Production Method
Sterility Testing — Hematopoietic Progenitor Cell — Apheresis Product
Donor Hemoglobin Instrumentation RFP
Acp-215 Cell Processor Implementation (Washed Red Blood Cells)
Feasibility Assessment of Using Stem Cell Patient Blood Product Support to Examine Changes in Blood
Component Manufacturing
Impact of Donor Sex, Age and Hemoglobin Status on Hemolysis
Cryopreservation of Gerbich/Leach Donor
Impact of Sample Tube Storage (Time and Temperature) on Platelet Count
RFP — Bact/Alert System
Investigation of an Adverse Transfusion Reaction
Rinse Modification to the Platelet Pooling Process
Evaluating the Efficacy of Skin Disinfectants when Combined with Natural Oils
Support Validation of Compolab Instrument
Why Do Platelets Have a “Cell Death” Receptor?
Analyses of Riboflavin/UV Light Treatment on Blood Products
Investigation of Leukoreduction Effectiveness in B2 Whole Blood with Incomplete Filtration
iv
Development in Collaboration with External Agencies
Haemonetics Solx/Fenwal ESol ACP-215 study
Terumo BCT Cationization Project: Phases I, II, and III
Haemonetics in vivo study
Evaluation of Bacterial Detection in Buffy Coat Platelet Concentrates by the pH Safe System
Evaluation of the Efficacy of the Mirasol® Pathogen Reduction Technology System to Eradicate
Biofilm-Forming Bacteria
INTERCEPT (Cerus) Pathogen Inactivation System
THERAFLEX (Macopharma) Pathogen Inactivation System
MIRASOL (Terumo BCT) Pathogen Inactivation System
Evaluation of DEHP-Free Pediatric Storage Bags — A Collaboration with Fresenius Kabi
Supernatant Reduction of Gamma-Irradiated RCC for pediatric transfusion — A Collaboration with the
IWK Health Centre in Halifax
Short and Long-Term Clinical Effects of Blood Donor Characteristics in Transfusion Recipients
Exploratory Analyses to Determine if Method of Donor Blood Processing Affects Outcome in
Transfused Recipients
Bacterial Study in Uganda
Participation in International Benchmarking Studies, Technology Evaluations and Knowledge
Exchange Activities
BEST 74 – Irradiation Study
BEST 76 – Donor Factors Associated with Low pH in Stored Apheresis Platelets
BEST 83 – Hemolysis Standardization
Titles of projects funded by National Training Program
Note: Projects that are italicized are those for which funding was initiated in fiscal year 2014–2015.
Canadian Blood Services/CIHR Partnership Post-Doctoral Fellowship program
A Novel Cell Surface Engineering Method for Universal Red Blood Donor Cells Via Combination of
Enzymatic Cleavage and Polymer Grafting
Post-Doctoral Fellowship program
Pathogenesis of Fetal and Neonatal Alloimmune Thrombocytopenia and Mechanisms of IVIg Therapy
Study of the Apoptosis Mechanism in Blood Processing and Platelet Storage in Order to Improve Stored
Platelet Quality After Pathogen Inactivation Treatment
Identification of a Two-Step Mechanism Responsible for Antibody-Mediated Transfusion Related Acute
Lung Injury (TRALI)
CD8+CD25+ Regulatory T Cells: Unveiling New Mechanisms and Treatment of ITP
Role of fc Receptors in Antibody-Mediated Immune Suppression
Transfusion Options in Coagulopathy: Efficacy in Controlling Bleeding
Understanding IVIg Mechanism(S) of Action in Alleviating Immune Platelet Destruction and
Thrombocytopenia
Understanding the Factors That Influence Bacterial Proliferation and Biofilm Formation in Platelet
Concentrates
Mechanism of Anti-D-Like Antibody-Mediated Amelioration of Immune Thrombocytopenia (ITP)
v
Graduate Fellowship program
Effect of Polymer Size and Species on Immunocamouflage and Antigenicity
The in vivo Effects of Liposome Treatment on Minimizing Membrane Injury in Rat Red Blood Cells
(RBCs) During Hypothermic Storage
Identification of Protein Biomarkers for Red Cell Quality
MRI Guided Focused Ultrasound Facilitated Ivig Immunotherapy as a Therapeutic Approach for
Alzheimer's Disease
Application of Microfluidic Technology to Blood Group Genotyping for Non-invasive Prenatal Diagnosis
of Fetal RhD Status
Relationship of Warm Autoimmune Hemolytic Anemia to Normal Red Cell Senescence
Organ Specific Macromolecular Iron Chelators: Towards Effective Prevention of Transfusional Iron
overload
Assessment of Fluorinated Ice Crystallization Inhibitors; Cryopreservation of Hematopoietic Stem Cells
and Red Blood Cells
Characterization of the Role of Msi2 in Human Hematopoietic Stem Cell Self-Renewal
Role of Skin Disinfection and Buffy Coat Platelet Production on Residual Bacterial Contamination in
Platelet Concentrates and Cord Blood Stem Cells
Novel Mechanisms of Plasma Fibronectin in Hemostasis, Cryoprecipitate Therapy and Platelet Storage:
Potential Applications in Transfusion Medicine
Mechanism of Transplacental Transport of IgGs, and IVIg and Anti-FcRn Therapies in the Treatment of
Fetal and Neonatal Alloimmune Thrombocytopenia
Study of the Role of Platelet microRNAs
Studies on the Development of Biocompatible Antimicrobial Platelet Storage Devices
Towards the Impact of Protein Synthesis in Human Platelets to Transfusion Medicine
Investigation of Pathophysiology, Prevention and Treatment of Murine Transfusion Related Acute Lung
Injury (TRALI)
Cellular Therapy to Improve CD4+ t-cell Responses in Humanized Mice Infected with HIV-1: Adoptive
Transfer of CD4+ t-cells Lacking s-Src Activity
Impact of Storage on the Function of Cord Blood Hematopoietic Stem and Progenitor Cells
Small Molecule Inhibitors of Phagocytosis to Replace Intravenous Immunoglobulin (IVIg)
Titles of projects funded by Program Support Award for Canadian Transfusion Medicine and
Science Research
McMaster Transfusion Research Program
University of Ottawa Centre for Transfusion Research
Centre for Blood Research Infrastructure Support for Transfusion Research
vi
Appendix II: Publications
Summary of peer-reviewed and non-peer-reviewed
publications from fiscal year 2014-2015
# of peer-reviewed and non-peer-reviewed publications in
fiscal year 2014-15
296
Peer-reviewed publications
254
Journal articles
113
Review articles
10
Clinical guidelines
2
Comments/Letters
11
Published abstracts
116
Canadian Blood Services Circular of Information
2
Non-peer-reviewed publications
42
Canadian Blood Services website publications
15
Technical reports
24
Theses
3
h-Index
Summary of h-index factor analysis
Productivity and Impact of Core Investigators
45
40
35
30
25
20
15
10
5
0
H-Index
H-Index (past 5 years)
Mean H-Index
A
B
C
D
E
F G H I J K
Core Investigator
L
M N
O
Mean H-Index (past 5
years)
Notes: i) H‐Index factors measured using GoogleScholar on April 10 2015. ii) Mean H‐ index calculated using H‐Index
factors from the 15 core investigators. iii) H‐Index is a single bibliometric indicator that is a measure of both the
productivity and impact of published work. H‐Index is an indicator of research users being aware of and valuing published
research evidence. Core investigators include: Jason Acker, John Blake, Donald Branch, Dana Devine, Margaret Fearon,
Mindy Goldman, Alan Lazarus, Heyu Ni, Sheila O’Brien, Nicolas Pineault, Ed Pryzdial, Sandra Ramirez, Mark Scott,
William Sheffield, and Kathryn Webert. Average overall H-index for Canadian university professors in the biological
sciences is 10.6.
vii
Publications’ details
Author Legend:
Bold – Centre for Innovation core investigators and senior staff; Canadian Blood Services medical
directors; directors of transfusion medicine research programs receiving funding via the Program
Support Award.
Underlined – Non-Canadian Blood Services investigators funded in part by Canadian Blood Services.
Journal articles
1.
Acker JP, Hansen AL, Kurach JD, Turner TR, Croteau I, Jenkins C. A Quality Monitoring Program
for Red Blood Cell Components: In Vitro Quality Indicators before and after Implementation of
Semiautomated Processing. Transfusion 2014; 54: 2534-43.
2.
Akyurekli C, Le Y, Richardson RB, Fergusson D, Tay J, Allan DS. A Systematic Review of Preclinical
Studies on the Therapeutic Potential of Mesenchymal Stromal Cell-Derived Microvesicles. Stem Cell
Rev 2015; 11: 150-60.
3.
Alak A, Jerzak KJ, Quirt JA, Lane SJ, Miller PA, Haider S, Arnold DM. How to Succeed in Research
During Medical Training: A Qualitative Study. Clin Invest Med 2014; 37: E117.
4.
Alam A, Huang M, Yi Q-L, Lin Y, Hannach B. Perioperative Transfusion-Related Acute Lung Injury:
The Canadian Blood Services Experience. Transfus Apher Sci 2014; 50: 392-8.
5.
Arnold DM. Vancomycin. Reactions Weekly 2015; 1538: 235.
6.
Arnold DM, Curtis BR, Bakchoul T, for the Subcommittee on Platelet Immunology. Recommendations
for Standardization of Laboratory Testing for Drug-Induced Immune Thrombocytopenia:
Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis 2015; 13: 676-8.
7.
Arnold DM, Nazi I, Toltl LJ, Ross C, Ivetic N, Smith JW, Liu Y, Kelton JG. Antibody Binding to
Megakaryocytes in Vivo in Patients with Immune Thrombocytopenia. Eur J Haematol 2015.
8.
Barty RL, Gagliardi K, Owens W, Lauzon D, Scheuermann S, Liu Y, Wang G, Pai M, Heddle NM. A
Benchmarking Program to Reduce Red Blood Cell Outdating: Implementation, Evaluation, and a
Conceptual Framework. Transfusion 2015.
9.
Berger Pelletier E, Emond M, Lauzier F, Savard M, Turgeon AF. Hyperosmolar Therapy in Severe
Traumatic Brain Injury: A Survey of Emergency Physicians from a Large Canadian Province. PLoS One
2014; 9: e95778.
10. Bernardo L, Denomme GA, Shah K, Lazarus AH. RhD Specific Antibodies Are Not Detectable in
HLA-Drb1(*)1501 Mice Challenged with Human RhD Positive Erythrocytes. Adv Hematol 2014; 2014:
470242.
11. Bian Y, Chang TM. A Novel Nanobiotherapeutic Poly-[Hemoglobin-Superoxide Dismutase-CatalaseCarbonic Anhydrase] with No Cardiac Toxicity for the Resuscitation of a Rat Model with 90 Minutes of
Sustained Severe Hemorrhagic Shock with Loss of 2/3 Blood Volume. Artif Cells Nanomed Biotechnol
2015; 43: 1-9.
12. Bigham M, Konrad S, Van Buynder P, Van Buynder J, Isaac-Renton J, ElSherif M, Halperin SA. Low
Pertussis Toxin Antibody Levels in Two Regional Cohorts of Canadian Pregnant Women. Vaccine
2014; 32: 6493-8.
13. Blake JT, Hardy M. A Generic Modeling Framework to Evaluate Network Blood Management
Policies: The Canadian Blood Services Experience. Oper Res Health Care 2014; 3: 116-28.
14. Bloch EM, Sakac D, Branch HA, Cserti-Gazdewich C, Pendergrast J, Pavenski K, Branch DR. Western
Immunoblotting as a New Tool for Investigating Direct Antiglobulin Test-Negative Autoimmune
Hemolytic Anemias. Transfusion 2015.
15. Boutin A, Chasse M, Shemilt M, Lauzier F, Moore L, Zarychanski R, Lacroix J, Fergusson DA,
Desjardins P, Turgeon AF. Red Blood Cell Transfusion in Patients with Traumatic Brain Injury: A
Systematic Review Protocol. Syst Rev 2014; 3: 66.
16. Breau RH, Kokolo MB, Punjani N, Cagiannos I, Beck A, Niznick N, Buenaventura C, Cowan J, Knoll
G, Momoli F, Morash C, Ruzicka M, Schachkina S, Tinmouth A, Xie HY, Fergusson DA. The Effects
of Lysine Analogs During Pelvic Surgery: A Systematic Review and Meta-Analysis. Transfus Med Rev
2014; 28: 145-55.
17. Campbell IK, Miescher S, Branch DR, Mott PJ, Lazarus AH, Han D, Maraskovsky E, Zuercher AW,
Neschadim A, Leontyev D, McKenzie BS, Kasermann F. Therapeutic Effect of IVIG on Inflammatory
Arthritis in Mice Is Dependent on the Fc Portion and Independent of Sialylation or Basophils. J
Immunol 2014; 192: 5031-8.
18. Cembrowski GS, Clarke G. Quality Control of Automated Cell Counters. Clinics in Laboratory
Medicine 2015; 35: 59-71.
viii
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
Chapanian R, Kwan DH, Constantinescu I, Shaikh FA, Rossi NA, Withers SG, Kizhakkedathu JN.
Enhancement of Biological Reactions on Cell Surfaces Via Macromolecular Crowding. Nat Commun
2014; 5: 4683.
Chasse M, McIntyre L, Tinmouth A, Acker J, English SW, Knoll G, Forster A, Shehata N, Wilson K,
van Walraven C, Ducharme R, Fergusson DA. Clinical Effects of Blood Donor Characteristics in
Transfusion Recipients: Protocol of a Framework to Study the Blood Donor-Recipient Continuum. BMJ
Open 2015; 5: e007412.
Chen Y, Ge J, Ruan M, Zhu L, Xie Y, Xia R, Ni H, Zeng Q. [Study on the Relationship of Platelet
Specific-Autoantibodies with Therapeutic Outcomes by Dexamethasone in Immune Thrombocytopenia
Purpura]. Zhonghua Xue Ye Xue Za Zhi 2015; 36: 202-5.
Chen Z, Schubert P, Culibrk B, Devine DV. P38mapk Is Involved in Apoptosis Development in
Apheresis Platelet Concentrates after Riboflavin and Ultraviolet Light Treatment. Transfusion 2014.
Christou G, Kekre N, Petrcich W, Tokessy M, Neurath D, Giulivi A, Saidenberg E, McDiarmid S,
Atkins H, Bence-Bruckler I, Bredeson C, Huebsch L, Sabloff M, Sheppard D, Tay J, Tinmouth A,
Allan DS. Impact of Platelet Transfusion on Toxicity and Mortality after Hematopoietic Progenitor Cell
Transplantation. Transfusion 2015; 55: 253-8.
Chugh S, Darvish-Kazem S, Lim W, Crowther MA, Ghanima W, Wang G, Heddle NM, Kelton JG,
Arnold DM. Rituximab Plus Standard of Care for Treatment of Primary Immune Thrombocytopenia: A
Systematic Review and Meta-Analysis. The Lancet Haematology 2015; 2: e75-e81.
Corduan A, Ple H, Laffont B, Wallon T, Plante I, Landry P, Provost P. Dissociation of Serpine1 mRNA
from the Translational Repressor Proteins Ago2 and Tia-1 Upon Platelet Activation. Thromb Haemost
2015; 113.
Crow AR, Amash A, Lazarus AH. CD44 Antibody-Mediated Amelioration of Murine Immune
Thrombocytopenia (ITP): Mouse Background Determines the Effect of Fcgammariib Genetic
Disruption. Transfusion 2014.
da Silveira Cavalcante L, Acker JP, Holovati J. Differences in Rat and Human Erythrocytes Following
Blood Component Manufacturing: The Effect of Additive Solutions. Transfusion Medicine and
Hemotherapy 2015.
Dodd M, Marquez-Curtis L, Janowska-Wieczorek A, Hortelano G. Sustained Expression of
Coagulation Factor IX by Modified Cord Blood-Derived Mesenchymal Stromal Cells. J Gene Med
2014; 16: 131-42.
Dumont N, Boyer L, Emond H, Saltik BC, Pasha R, Bazin R, Mantovani D, Roy DC, Pineault N.
Medium Conditioned with Mesenchymal Stromal Cell-Derived Osteoblasts Improves the Expansion and
Engraftment Properties of Cord Blood Progenitors. Exp Hematol 2014; 42: 741-52.
Eder AF, Goldman M. Postdonation Information and Blood Component Retrievals: Realigning Blood
Center and Hospital Actions Based on Risk Assessment. Transfus Med Rev 2014; 28: 226-34.
Eltringham-Smith LJ, Lei X, Reheman A, Lambourne MD, Pryzdial EL, Ni H, Sheffield WP. The
Fibrinogen but Not the Factor VIII Content of Transfused Plasma Determines Its Effectiveness at
Reducing Bleeding in Coagulopathic Mice. Transfusion 2014.
Estey MP, Clarke G, Sia W, Toor E, Higgins TN. A Mother and Newborn with Brown Blood. Clin
Chem 2015; 61: 466-9.
Figueiredo CA, Drohomyrecky PC, McCarthy SDS, Leontyev D, Ma X-Z, Branch DR, Dunn SE.
Optimal Attenuation of Experimental Autoimmune Encephalomyelitis by Intravenous Immunoglobulin
Requires an Intact Interleukin-11 Receptor. PLoS One 2014; 9: e101947.
Garcia F, Rodriguez M-A, Goldman M, Azcarate M-N, Rodriguez M-I, Muniz-Diaz E, Puente F,
Alshatti H, Haimila K, Molano A, Garaizar A, Ochoa-Garay G. New RHD Variant Alleles. Transfusion
2015; 55: 427-9.
Garg AX, Nevis IF, McArthur E, Sontrop JM, Koval JJ, Lam NN, Hildebrand AM, Reese PP, Storsley
L, Gill JS, Segev DL, Habbous S, Bugeja A, Knoll GA, Dipchand C, Monroy-Cuadros M, Lentine KL.
Gestational Hypertension and Preeclampsia in Living Kidney Donors. N Engl J Med 2015; 372: 124-33.
Ghobadloo SM, Balcerzak AK, Gargaun A, Muharemagic D, Mironov GG, Capicciotti CJ, Briard JG,
Ben RN, Berezovski MV. Carbohydrate-Based Ice Recrystallization Inhibitors Increase Infectivity and
Thermostability of Viral Vectors. Sci Rep 2014; 4: 5903.
Gierczak RF, Pepler L, Bhagirath V, Liaw PC, Sheffield WP. Alpha-1 Proteinase Inhibitor M358r
Reduces Thrombin Generation When Displayed on the Surface of Cells Expressing Tissue Factor.
Thromb Res 2014; 134: 1142-9.
Griesdale DE, Sekhon MS, Menon DK, Lavinio A, Donnelly J, Robba C, Sekhon IS, Taylor A,
Henderson WR, Turgeon AF, Gupta AK. Hemoglobin Area and Time Index above 90 G/L Are
ix
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
Associated with Improved 6-Month Functional Outcomes in Patients with Severe Traumatic Brain
Injury. Neurocrit Care 2014.
Gul-Uludağ H, Valencia-Serna J, Kucharski C, Marquez-Curtis LA, Jiang X, Larratt L, JanowskaWieczorek A, Uludağ H. Polymeric Nanoparticle-Mediated Silencing of CD44 Receptor in Cd34+
Acute Myeloid Leukemia Cells. Leukemia Res 2014; 38: 1299-308.
Guo Q, Duffy SP, Matthews K, Santoso AT, Scott MD, Ma H. Microfluidic Analysis of Red Blood Cell
Deformability. J Biomech 2014; 47: 1767-76.
Hansen AL, Kurach JDR, Turner TR, Jenkins C, Busch MP, Norris PJ, Dugger J, Tomasulo PA,
Devine DV, Acker JP. The Effect of Processing Method on the in Vitro Characteristics of Red Blood
Cell Products. Vox Sang 2015.
Haspel RL, Lin Y, Mallick R, Tinmouth A, Cid J, Eichler H, Lozano M, van de Watering L, Fisher PB,
Ali A, Parks E. Internal Medicine Resident Knowledge of Transfusion Medicine: Results from the
BEST-TEST International Education Needs Assessment. Transfusion 2014.
Hebert PC, Fergusson DA, Hutton B, Mazer CD, Fremes S, Blajchman M, MacAdams C, Wells G,
Robblee J, Bussieres J, Teoh K. Regulatory Decisions Pertaining to Aprotinin May Be Putting Patients
at Risk. CMAJ 2014; 186: 1379-86.
Heddle NM, Eikelboom J, Liu Y, Barty R, Cook RJ. Exploratory Studies on the Age of Transfused
Blood and in-Hospital Mortality in Patients with Cardiovascular Diagnoses. Transfusion 2015; 55: 36472.
Hesketh CC, Knoll GA, Molnar AO, Tsampalieros A, Zimmerman DL. Vitamin D and Kidney
Transplant Outcomes: A Protocol for a Systematic Review and Meta-Analysis. Syst Rev 2014; 3: 64.
Hsia C, Liu Y, Eckert K, Monga N, Elia-Pacitti J, Heddle NM. Intravenous Immunoglobulin (IVIg)
Utilization in Immune Thrombocytopenia (ITP): A Multi-Center, Retrospective Review. Drugs - Real
World Outcomes 2015; 2: 35-42.
Jimenez-Diaz MB, Ebert D, Salinas Y, Pradhan A, Lehane AM, Myrand-Lapierre ME, O'Loughlin KG,
Shackleford DM, Justino de Almeida M, Carrillo AK, Clark JA, Dennis AS, Diep J, Deng X, Duffy S,
Endsley AN, Fedewa G, Guiguemde WA, Gomez MG, Holbrook G, Horst J, Kim CC, Liu J, Lee MC,
Matheny A, Martinez MS, Miller G, Rodriguez-Alejandre A, Sanz L, Sigal M, Spillman NJ, Stein PD,
Wang Z, Zhu F, Waterson D, Knapp S, Shelat A, Avery VM, Fidock DA, Gamo FJ, Charman SA,
Mirsalis JC, Ma H, Ferrer S, Kirk K, Angulo-Barturen I, Kyle DE, DeRisi JL, Floyd DM, Guy RK. (+)Sj733, a Clinical Candidate for Malaria That Acts through Atp4 to Induce Rapid Host-Mediated
Clearance of Plasmodium. Proc Natl Acad Sci U S A 2014; 111: E5455-62.
Kayibanda JF, Hiremath S, Knoll GA, Fergusson D, Chow BJ, Shabana W, Akbari A. Does Intravenous
Contrast-Enhanced Computed Tomography Cause Acute Kidney Injury? Protocol of a Systematic
Review of the Evidence. Syst Rev 2014; 3: 94.
Knoll GA, Humar A, Fergusson D, Johnston O, House AA, Kim SJ, Ramsay T, Chasse M, Pang X,
Zaltzman J, Cockfield S, Cantarovich M, Karpinski M, Lebel L, Gill JS. Levofloxacin for Bk Virus
Prophylaxis Following Kidney Transplantation: A Randomized Clinical Trial. Jama 2014; 312: 210614.
Knoll GA, Kokolo MB, Mallick R, Beck A, Buenaventura CD, Ducharme R, Barsoum R, Bernasconi C,
Blydt-Hansen TD, Ekberg H, Felipe CR, Firth J, Gallon L, Gelens M, Glotz D, Gossmann J, Guba M,
Morsy AA, Salgo R, Scheuermann EH, Tedesco-Silva H, Vitko S, Watson C, Fergusson DA. Effect of
Sirolimus on Malignancy and Survival after Kidney Transplantation: Systematic Review and MetaAnalysis of Individual Patient Data. BMJ 2014; 349: g6679.
Kosan C, Rashkovan M, Ross J, Schaffer AM, Saba I, Lemsaddek W, Trudel M, Moroy T. The
Transcription Factor Miz-1 Is Required for Embryonic and Stress-Induced Erythropoiesis but
Dispensable for Adult Erythropoiesis. Am J Blood Res 2014; 4: 7-19.
Kumar A, Mhaskar R, Grossman BJ, Kaufman RM, Tobian AA, Kleinman S, Gernsheimer T,
Tinmouth AT, Djulbegovic B. Platelet Transfusion: A Systematic Review of the Clinical Evidence.
Transfusion 2014.
Lacroix J, Hebert PC, Fergusson DA, Tinmouth A, Cook DJ, Marshall JC, Clayton L, McIntyre L,
Callum J, Turgeon AF, Blajchman MA, Walsh TS, Stanworth SJ, Campbell H, Capellier G, Tiberghien
P, Bardiaux L, van de Watering L, van der Meer NJ, Sabri E, Vo D. Age of Transfused Blood in
Critically Ill Adults. N Engl J Med 2015; 372: 1410-8.
Lalu MM, Moher D, Marshall J, Fergusson D, Mei SH, Macleod M, Griffin G, Turgeon AF, Rudnicki
M, Fishman J, Avey MT, Skidmore B, Grimshaw JM, Stewart DJ, Singh K, McIntyre L. Efficacy and
Safety of Mesenchymal Stromal Cells in Preclinical Models of Acute Lung Injury: A Systematic
Review Protocol. Syst Rev 2014; 3: 48.
x
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
Lane SJ, Walker I, Chan AK, Heddle NM, Poon MC, Minuk L, Jardine L, Arnold E, Sholapur N,
Webert KE. Treatment Decision-Making among Canadian Youth with Severe Haemophilia: A
Qualitative Approach. Haemophilia 2015; 21: 180-9.
Leontyev D, Neschadim A, Branch DR. Cytokine Profiles in Mouse Models of Experimental Immune
Thrombocytopenia Reveal a Lack of Inflammation and Differences in Response to Intravenous
Immunoglobulin Depending on the Mouse Strain. Transfusion 2014; 54: 2871-9.
Lieberman L, Devine DV, Reesink HW, Panzer S, Wong J, Raison T, Benson S, Pink J, Leitner GC,
Horvath M, Compernolle V, Scuracchio PSP, Wendel S, Delage G, Nahirniak S, Dongfu X, Krusius T,
Juvonen E, Sainio S, Cazenave JP, Guntz P, Kientz D, Andreu G, Morel P, Seifried E, Hourfar K, Lin
CK, O'Riordan J, Raspollini E, Villa S, Rebulla P, Flanagan P, Teo D, Lam S, Ang AL, Lozano M,
Sauleda S, Cid J, Perreira A, Ekermo B, Niederhauser C, Waldvogel S, Fontana S, Desborough MJ,
Pawson R, Li M, Kamel H, Busch M, Qu L, Triulzi D. Prevention of Transfusion-Transmitted
Cytomegalovirus (CMV) Infection: Standards of Care. Vox Sang 2014; 107: 276-311.
Lieberman L, Liu Y, Portwine C, Barty RL, Heddle NM. An Epidemiologic Cohort Study Reviewing
the Practice of Blood Product Transfusions among a Population of Pediatric Oncology Patients.
Transfusion 2014; 54: 2736-44.
Mahan CE, Liu Y, Turpie AG, Vu JT, Heddle N, Cook RJ, Dairkee U, Spyropoulos AC. External
Validation of a Risk Assessment Model for Venous Thromboembolism in the Hospitalised Acutely-Ill
Medical Patient (Vte-Valourr). Thromb Haemost 2014; 112: 692-9.
Mahindra A, Raval G, Mehta P, Brazauskas R, Zhang MJ, Zhong X, Bird JM, Freytes CO, Hale GA,
Herzig R, Holmberg LA, Kamble RT, Kumar S, Lazarus HM, Majhail NS, Marks DI, Moreb JS, Olsson
R, Saber W, Savani BN, Schiller GJ, Tay J, Vogl DT, Waller EK, Wiernik PH, Wirk B, Lonial S,
Krishnan AY, Dispenzieri A, Brandenburg NA, Gale RP, Hari PN. New Cancers after
Autotransplantations for Multiple Myeloma. Biol Blood Marrow Transplant 2015; 21: 738-45.
Myrand-Lapierre ME, Deng X, Ang RR, Matthews K, Santoso AT, Ma H. Multiplexed Fluidic Plunger
Mechanism for the Measurement of Red Blood Cell Deformability. Lab Chip 2015; 15: 159-67.
Nazi I, Arnold DM, Moore JC, Smith JW, Ivetic N, Horsewood P, Warkentin TE, Kelton JG. Pitfalls in
the Diagnosis of Heparin-Induced Thrombocytopenia: A 6-Year Experience from a Reference
Laboratory. Am J Hematol 2015.
Neschadim A, Pritzker LB, Pritzker KP, Branch DR, Summerlee AJ, Trachtenberg J, Silvertown JD.
Relaxin Receptor Antagonist at-001 Synergizes with Docetaxel in Androgen-Independent Prostate
Xenografts. Endocr Relat Cancer 2014; 21: 459-71.
Neunert C, Noroozi N, Norman G, Buchanan GR, Goy J, Nazi I, Kelton JG, Arnold DM. Severe
Bleeding Events in Adults and Children with Primary Immune Thrombocytopenia: A Systematic
Review. Journal of Thrombosis and Haemostasis 2015; 13: 457-64.
Newbold KB, Heddle NM, Lane SJ, Arnold E, Eyles J, Webert K. Risks, Benefits and the Role of
Stakeholders in Pathogen Reduction Technology. Health Risk Soc 2014; 16: 547-64.
Osman A, Hitzler WE, Meyer CU, Landry P, Corduan A, Laffont B, Boilard E, Hellstern P, Vamvakas
EC, Provost P. Effects of Pathogen Reduction Systems on Platelet Micrornas, mRNAs, Activation, and
Function. Platelets 2015; 26: 154-63.
Palmer DS, Scalia V, O'Toole J, Welch C, Yi Q, Goldman M. Incidence of Gammopathies in LongTerm Plasmapheresis Donors at Canadian Blood Services. Transfusion 2015.
Pilon S, Jedrysiak D, Sheppard D, Bredeson CN, Tay J, Allan DS. Current Trends in Clinical Studies of
Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2015; 21: 364-70.
Prudova A, Serrano K, Eckhard U, Fortelny N, Devine DV, Overall CM. Tails N-Terminomics of
Human Platelets Reveals Pervasive Metalloproteinase-Dependent Proteolytic Processing in Storage.
Blood 2014; 124: e49-60.
Pryzdial EL, Sutherland MR, Ruf W. The Procoagulant Envelope Virus Surface: Contribution to
Enhanced Infection. Thromb Res 2014; 133: S15-7.
Quest GR, Gaal H, Clarke G, Nahirniak S. Transfusion-Related Acute Lung Injury after Transfusion of
Pooled Immune Globulin: A Case Report. Transfusion 2014.
Ramirez-Arcos S, Kou Y, Perkins H. Evaluation of a Universal Point-of-Issue Assay for Bacterial
Detection in Buffy Coat Platelet Components. Vox Sang 2014; 107: 192-5.
Ramirez-Arcos S, Kou Y, Yang L, Perkins H, Taha M, Halpenny M, Elmoazzen H. Validation of
Sterility Testing of Cord Blood: Challenges and Results. Transfusion 2015.
Rimmer E, Houston BL, Kumar A, Abou-Setta AM, Friesen C, Marshall JC, Rock G, Turgeon AF,
Cook DJ, Houston DS, Zarychanski R. The Efficacy and Safety of Plasma Exchange in Patients with
Sepsis and Septic Shock: A Systematic Review and Meta-Analysis. Crit Care 2014; 18: 699.
xi
75.
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
90.
91.
92.
93.
Rodger M, Sheppard D, Gandara E, Tinmouth A. Haematological Problems in Obstetrics. Best Pract
Res Clin Obstet Gynaecol 2015.
Sanders S, Bredeson C, Pringle CE, Martin L, Allan D, Bence-Bruckler I, Hamelin L, Hopkins HS,
Sabloff M, Sheppard D, Tay J, Huebsch L, Atkins HL. Autologous Stem Cell Transplantation for Stiff
Person Syndrome: Two Cases from the Ottawa Blood and Marrow Transplant Program. JAMA Neurol
2014; 71: 1296-9.
Schubert P, Culibrk B, Karwal S, Serrano K, Levin E, Bu D, Bhakta V, Sheffield WP, Goodrich RP,
Devine DV. Whole Blood Treated with Riboflavin and Ultraviolet Light: Quality Assessment of All
Blood Components Produced by the Buffy Coat Method. Transfusion 2014.
Schulze HG, Atkins CG, Devine DV, Blades MW, Turner RF. Fully Automated Decomposition of
Raman Spectra into Individual Pearson's Type VII Distributions Applied to Biological and Biomedical
Samples. Appl Spectrosc 2015; 69: 26-36.
Shannon CP, Balshaw R, Ng RT, Wilson-McManus JE, Keown P, McMaster R, McManus BM,
Landsberg D, Isbel NM, Knoll G, Tebbutt SJ. Two-Stage, in Silico Deconvolution of the Lymphocyte
Compartment of the Peripheral Whole Blood Transcriptome in the Context of Acute Kidney Allograft
Rejection. PLoS One 2014; 9: e95224.
Shao L, Wu Y, Zhou H, Qin P, Ni H, Peng J, Hou M. Successful Treatment with Oseltamivir Phosphate
in a Patient with Chronic Immune Thrombocytopenia Positive for Anti-GPIb/IX Autoantibody. Platelets
2014: 1-3.
Sharma M, Zhang MJ, Zhong X, Abidi MH, Akpek G, Bacher U, Callander NS, Dispenzieri A, Freytes
CO, Fung HC, Gale RP, Gasparetto C, Gibson J, Holmberg LA, Kindwall-Keller TL, Klumpp TR,
Krishnan AY, Landau HJ, Lazarus HM, Lonial S, Maiolino A, Marks DI, Mehta P, Mikhael Med JR,
Nishihori T, Olsson R, Ramanathan M, Roy V, Savani BN, Schouten HC, Scott E, Tay J, To LB, Vesole
DH, Vogl DT, Hari P. Older Patients with Myeloma Derive Similar Benefit from Autologous
Transplantation. Biol Blood Marrow Transplant 2014; 20: 1796-803.
Sharpe C, Lane D, Cote J, Hosseini-Maaf B, Goldman M, Olsson ML, Hult AK. Mixed Field
Reactions in ABO and Rh Typing Chimerism Likely Resulting from Twin Haematopoiesis. Blood
Transfus 2014; 12: 608-10.
Sheffield WP, Eltringham-Smith LJ, Gataiance S, Bhakta V. A Plasmin-Activatable Thrombin Inhibitor
Reduces Experimental Thrombosis and Assists Experimental Thrombolysis in Murine Models. J
Thromb Thrombolysis 2014.
Sheffield WP, Lambourne MD, Eltringham-Smith LJ, Bhakta V, Arnold DM, Crowther MA. -S195a
Thrombin Reduces the Anticoagulant Effects of Dabigatran in Vitro and in Vivo. J Thromb Haemost
2014; 12: 1110-5.
Shehata N, Forster A, Lawrence N, Rothwell DM, Fergusson D, Tinmouth A, Wilson K. Changing
Trends in Blood Transfusion: An Analysis of 244,013 Hospitalizations. Transfusion 2014.
Shih AW, Kolesar E, Ning S, Manning N, Arnold DM, Crowther MA. Evaluation of the
Appropriateness of Frozen Plasma Usage after Introduction of Prothrombin Complex Concentrates: A
Retrospective Study. Vox Sang 2015; 108: 274-80.
Song F, Zhu Y, Shi Z, Tian J, Deng X, Ren J, Andrews MC, Ni H, Ling W, Yang Y. Plant Food
Anthocyanins Inhibit Platelet Granule Secretion in Hypercholesterolaemia: Involving the Signalling
Pathway of Pi3k–Akt. Thromb Haemost 2014; 112: 981-91.
Squires JE, Grimshaw JM, Taljaard M, Linklater S, Chasse M, Shemie SD, Knoll GA. Design,
Implementation, and Evaluation of a Knowledge Translation Intervention to Increase Organ Donation
after Cardiocirculatory Death in Canada: A Study Protocol. Implement Sci 2014; 9: 80.
Taha M, Kalab M, Yi QL, Landry C, Greco-Stewart V, Brassinga AK, Sifri CD, Ramirez-Arcos S.
Biofilm-Forming Skin Microflora Bacteria Are Resistant to the Bactericidal Action of Disinfectants
Used During Blood Donation. Transfusion 2014; 54: 2974-82.
Talreja H, Akbari A, White CA, Ramsay TO, Hiremath S, Knoll G. Predicting Kidney Transplantation
Outcomes Using Proteinuria Ascertained from Spot Urine Samples Versus Timed Urine Collections. Am
J Kidney Dis 2014; 64: 962-8.
Taylor BJ, Howell A, Martin KA, Manage DP, Gordy W, Campbell SD, Lam S, Jin A, Polley SD,
Samuel RA, Atrazhev A, Stickel AJ, Birungi J, Mbonye AK, Pilarski LM, Acker JP, Yanow SK. A
Lab-on-Chip for Malaria Diagnosis and Surveillance. Malar J 2014; 13: 179.
Teitelbaum L, Metcalfe A, Clarke G, Parboosingh JS, Wilson RD, Johnson JM. Costs and Benefits of
Non-Invasive Fetal RhD Determination. Ultrasound in Obstetrics & Gynecology 2015; 45: 84-8.
Thomas SM, Lam NN, Huang A, Nash DM, Prasad GV, Knoll GA, Koval JJ, Lentine KL, Kim SJ,
Alam A, Lok CE, Treleaven DJ, Garg AX. Risk of Serious Gastrointestinal Bleeding in Living Kidney
Donors. Clin Transplant 2014; 28: 530-9.
xii
94.
95.
96.
97.
98.
99.
100.
101.
102.
103.
104.
105.
106.
107.
108.
109.
110.
111.
112.
Traore AN, Chan AKC, Webert KE, Heddle N, Ritchie B, St-Louis J, Teitel J, Lillicrap D, Iorio A,
Walker I. First Analysis of 10-Year Trends in National Factor Concentrates Usage in Haemophilia: Data
from CHARMS, the Canadian Hemophilia Assessment and Resource Management System.
Haemophilia 2014; 20: e251-e9.
van der Meer PF, Dumont LJ, Lozano M, Bondar N, Wong J, Ismay S, Pink J, Nussbaumer W, Coene J,
Feys HB, Compernolle V, Devine DV, Howe D, Lin CK, Sun J, Ringwald J, Strasser EF, Eckstein R,
Seltsam A, Perseghin P, Proserpio P, Wakamoto S, Akino M, Takamoto S, Tadokoro K, Teo D, Shu PH,
Chua SS, Jimenez-Marco T, Lozano M, Cid J, Castro E, Muñoz I, Gulliksson H, Sandgren P, Thomas S,
Petrik J, McColl K, Kamel H, Dugger J, Sweeney JD, Gorlin JB, Sutor LJ, Heath D, Sayers MH.
Aggregates in Platelet Concentrates. Vox Sang 2015; 108: 96-100.
van Schalkwyk J, Nourmoussavi M, Massey A, Gustafson R, Brodkin E, Petric M, Krajden M, Dobson
S, Buxton J, Bigham M, Pick N, Schreiber R, Sherlock CH, Money D, Yoshida EM. Missed
Opportunities for Prevention of Perinatal Transmission of Hepatitis B: A Retrospective Cohort Study.
Can J Gastroenterol Hepatol 2014; 28: 525-8.
Vassen L, Beauchemin H, Lemsaddek W, Krongold J, Trudel M, Moroy T. Growth Factor
Independence 1b (Gfi1b) Is Important for the Maturation of Erythroid Cells and the Regulation of
Embryonic Globin Expression. PLoS One 2014; 9: e96636.
Veljkovic V, Glisic S, Muller CP, Scotch M, Branch DR, Perovic VR, Sencanski M, Veljkovic N,
Colombatti A. In Silico Analysis Suggests Interaction between Ebola Virus and the Extracellular Matrix.
Front Microbiol 2015; 6: 135.
Veljkovic V, Loiseau PM, Figadere B, Glisic S, Veljkovic N, Perovic VR, Cavanaugh DP, Branch DR.
Virtual Screen for Repurposing Approved and Experimental Drugs for Candidate Inhibitors of Ebola
Virus Infection. F1000Res 2015; 4: 34.
Vuong J, Qiu Y, La M, Clarke G, Swinkels DW, Cembrowski G. Reference Intervals of Complete
Blood Count Constituents Are Highly Correlated to Waist Circumference: Should Obese Patients Have
Their Own “Normal Values?”. Am J Hematol 2014; 89: 671-7.
Wang A, Kluger R. Increasing Efficiency in Protein-Protein Coupling: Subunit-Directed Acetylation
and Phase-Directed CuAAC ("Click Coupling") in the Formation of Hemoglobin Bis-Tetramers.
Biochemistry 2014; 53: 6793-9.
Wang Y, Reheman A, Spring CM, Kalantari J, Marshall AH, Wolberg AS, Gross PL, Weitz JI, Rand
ML, Mosher DF, Freedman J, Ni H. Plasma Fibronectin Supports Hemostasis and Regulates
Thrombosis. J Clin Invest 2014; 124: 4281-93.
Warkentin TE, Arnold DM, Nazi I, Kelton JG. The Platelet Serotonin-Release Assay. Am J Hematol
2015.
Williamson LM, Benjamin RJ, Devine DV, Katz LM, Pink J, for the Alliance of Blood Operators
Medical Directors Group. A Clinical Governance Framework for Blood Services. Vox Sang 2015.
Yougbaré I, Lang S, Yang H, Chen P, Zhao X, Tai W-S, Zdravic D, Vadasz B, Li C, Piran S, Marshall
A, Zhu G, Tiller H, Killie MK, Boyd S, Leong-Poi H, Wen X-Y, Skogen B, Adamson SL, Freedman J,
Ni H. Maternal Anti-Platelet Β3 Integrins Impair Angiogenesis and Cause Intracranial Hemorrhage. The
Journal of Clinical Investigation 2015; 125: 1545-56.
Yu H, Stowell SR, Bernardo L, Hendrickson JE, Zimring JC, Amash A, Uchikawa M, Lazarus AH.
Antibody-Mediated Immune Suppression of Erythrocyte Alloimmunization Can Occur Independently
from Red Cell Clearance or Epitope Masking in a Murine Model. J Immunol 2014; 193: 2902-10.
Yu X, Menard M, Seabright G, Crispin M, Lazarus AH. A Monoclonal Antibody with Anti-D–Like
Activity in Murine Immune Thrombocytopenia Requires Fc Domain Function for Immune
Thrombocytopenia Ameliorative Effects. Transfusion 2015.
Yudin J, Heddle NM. A 13-Question Approach to Resolving Serological Discrepancies in the
Transfusion Medicine Laboratory. Lab Med 2014; 45: 193-206.
Zapata A, Ramirez-Arcos S. A Comparative Study of Mcfarland Turbidity Standards and the Densimat
Photometer to Determine Bacterial Cell Density. Curr Microbiol 2015.
Zarychanski R, Abou-Setta AM, Kanji S, Turgeon AF, Kumar A, Houston DS, Rimmer E, Houston BL,
McIntyre L, Fox-Robichaud AE, Hebert P, Cook DJ, Fergusson DA. The Efficacy and Safety of
Heparin in Patients with Sepsis: A Systematic Review and Metaanalysis. Crit Care Med 2015; 43: 5118.
Zhou H, Hou Y, Liu X, Qiu J, Feng Q, Wang Y, Zhang X, Min Y, Shao L, Liu X, Li G, Li L, Yang L,
Xu S, Ni H, Peng J, Hou M. Low-Dose Decitabine Promotes Megakaryocyte Maturation and Platelet
Production in Healthy Controls and Immune Thrombocytopenia. Thromb Haemost 2015.
Zhurova M, Lusianti RE, Higgins AZ, Acker JP. Osmotic Tolerance Limits of Red Blood Cells from
Umbilical Cord Blood. Cryobiology 2014; 69: 48-54.
xiii
113. Zhurova M, McGann LE, Acker JP. Osmotic Parameters of Red Blood Cells from Umbilical Cord
Blood. Cryobiology 2014; 68: 379-88.
114. Zimmerman DL, Ruzicka M, Hebert P, Fergusson D, Touyz RM, Burns KD. Short Daily Versus
Conventional Hemodialysis for Hypertensive Patients: A Randomized Cross-over Study. PLoS One
2014; 9: e97135.
Review Articles
1.
Balcerzak AK, Capicciotti CJ, Briard JG, Ben RN. Designing Ice Recrystallization Inhibitors: From
Antifreeze (Glyco)Proteins to Small Molecules. RSC Advances 2014; 4: 42682-96.
2.
Devine DV, Chen D. A Fresh Look at Measuring Quality in Blood Components. ISBT Science Series
2014; 9: 148-54.
3.
Hadjesfandiari N, Yu K, Mei Y, Kizhakkedathu JN. Polymer Brush-Based Approaches for the
Development of Infection-Resistant Surfaces. Journal of Materials Chemistry B 2014; 2: 4968-78.
4.
Neschadim A, Branch DR. Mouse Models of Autoimmune Diseases: Immune Thrombocytopenia. Curr
Pharm Des 2015.
5.
Vadasz B, Chen P, Yougbaré I, Zdravic D, Li J, Li C, Carrim N, Ni H. Platelets and
Platelet alloantigens: Lessons from Human Patients and Animal Models of Fetal and Neonatal
Alloimmune Thrombocytopenia. Genes & Diseases 2015.
6.
Walsh GM, Devine DV. How to Get a Paper Published. ISBT Science Series 2014; 9: 56-63.
7.
Yu K, Mei Y, Hadjesfandiari N, Kizhakkedathu JN. Engineering Biomaterials Surfaces to Modulate the
Host Response. Colloids Surf B Biointerfaces 2014; 124: 69-79.
8.
Zeller MP, Al-Habsi KS, Golder M, Walsh GM, Sheffield WP. Plasma and Plasma Protein Product
Transfusion: A Canadian Blood Services Centre for Innovation Symposium. Transfus Med Rev 2015.
9.
Zeller MP, Al-Habsi KS, Heddle NM. Prophylactic Platelet Transfusions: Should They Be a Treatment
of the Past? Curr Opin Hematol 2014; 21: 521-7.
Clinical Guidelines
1.
Kaufman RM, Djulbegovic B, Gernsheimer T, Kleinman S, Tinmouth AT, Capocelli KE, Cipolle MD,
Cohn CS, Fung MK, Grossman BJ, Mintz PD, O'Malley BA, Sesok-Pizzini DA, Shander A, Stack GE,
Webert KE, Weinstein R, Welch BG, Whitman GJ, Wong EC, Tobian AAR. Platelet Transfusion: A
Clinical Practice Guideline from the AABB. Annals of Internal Medicine 2015; 162: 205-13.
2.
Nahirniak S, Slichter SJ, Tanael S, Rebulla P, Pavenski K, Vassallo R, Fung M, Duquesnoy R, Saw CL, Stanworth S, Tinmouth A, Hume H, Ponnampalam A, Moltzan C, Berry B, Shehata N. Guidance on
Platelet Transfusion for Patients with Hypoproliferative Thrombocytopenia. Transfus Med Rev 2015;
29: 3-13.
Comments/Letters
1.
Cembrowski G, Topping K, Clarke G. Within-Individual Mean Corpuscular Volume Variation. Arch
Pathol Lab Med 2014; 138: 1265.
2.
Estey MP, Capote KR, Barakauskas VE, Clarke G, Higgins T. Hemoglobin C in a Patient with Sickle
Cell Anemia: Transfusion-Acquired Sc Disease. Clin Biochem 2015; 48: 463-4.
3.
Goldman M, Lapierre D, Lemay L, Devine D, Sher G. Donor Criteria for Men Who Have Sex with
Men: A Canadian Perspective. Transfusion 2014; 54: 1887-92.
4.
Jansen AJG, Peng J, Zhao H-G, Hou M, Ni H. Sialidase Inhibition to Increase Platelet Counts: A New
Treatment Option for Thrombocytopenia. Am J Hematol 2015.
5.
Li AH, Dixon S, Prakash V, Kim SJ, Knoll GA, Lam NN, Garg AX. Physician Registration for
Deceased Organ Donation. Jama 2014; 312: 291-3.
6.
Ponnampalam A, Growe G, Loftus P, Chipperfield K, Bigham M. Acquired Peanut Hypersensitivity
Following Platelet Transfusion. Transfus Med 2014; 24: 426-7.
7.
Sandler SG, Eder AF, Goldman M, Winters JL. The Entity of Immunoglobulin a–Related Anaphylactic
Transfusion Reactions Is Not Evidence Based. Transfusion 2015; 55: 199-204.
8.
Shih A, Arnold DM. Plasma Transfusion Trials and Tribulations. Transfusion 2015; 55: 14-6.
9.
van Walraven C, Manuel D, Knoll G. In Reply to 'Dialysis Vintage Could Confound Survival Trends in
Esrd Patients'. Am J Kidney Dis 2014; 64: 156.
10. von Gunten S, Shoenfeld Y, Blank M, Branch DR, Vassilev T, Kasermann F, Bayry J, Kaveri S, Simon
HU. IVIG Pluripotency and the Concept of Fc-Sialylation: Challenges to the Scientist. Nat Rev Immunol
2014; 14: 349.
11. Zeller M, Arnold DM. Risk Infection to Spare Bleeding? The Quandary of Splenectomy for Immune
Thrombocytopenia. Am J Hematol 2015; 90: 271-2.
xiv
Published Abstracts
1.
Acker J, Holovati J, Cavalcante LS. Membrane Stabilizing Effect of Liposomes on Rat Red Blood
Cells. Biopreservation and Biobanking 2014; 12: A-10.
2.
Acker JP. Pre-Cryopreservation Processing and Storage: A Biologist’s Perspective on the Balance
between Manufacturing Efficiency and Post-Thaw Quality. Cryobiology 2014; 69: 512.
3.
Acker JP. The Science of Freezing Blood Cells. International Society for Biological and Environmental
Repositories Website 2014: 33.
4.
Alsheikh M, Pasha R, Pineault N. Characterization of the Hematopoietic Supporting Activity of
Osteoblasts Derived from Bone Marrow Mesenchymal Stromal Cells. Blood 2014; 124: 4358.
5.
Arbaeen AF, Levin E, Serrano K, Devine D. The Efficiency of Thromboelastography (TEG) to
Discriminate Good Vs. Poor Quality of Buffy Coat Platelet Concentrates. Transfusion 2014; 54: 77A.
6.
Arnold DM, Clare R, Salib M, Clayden R, Wang G, Nazi I, Kelton JG. The McMaster ITP Registry:
Assessing the Prevalence, Clinical and Laboratory Features of Immune Thrombocytopenia. Blood 2014;
124: 5008.
7.
Basta M, Branch DR. 7th International Immunoglobulin Conference: Mechanisms of Action. Clinical
& Experimental Immunology 2014; 178: 87-8.
8.
Beak C, Allan DS, Charge SB, Isasi R, Knoppers BM. Developing Educational Resources to Advance
Ethical Umbilical Cord Blood Research: A Canadian Perspective. Canadian Blood and Marrow
Transplant Group Website 2014.
9.
Beak C, Charge SB, Isasi R, Knoppers BM. Developing Educational Resources to Advance Ethical
Umbilical Cord Blood Research: A Canadian Perspective. Canadian Society For Transfusion Medicine
Website 2014.
10. Bernardo Reyes L, Amash A, Lazarus A. Antibody-Mediated Immune Suppression Induced by AntiRBC Antibodies Increases in Effectiveness When Mixtures of Monoclonal Antibodies Are Used. Vox
Sang 2014; 107: 167-8.
11. Berry B, Clarke G, Nahirniak S. A Tale of Two Cities (and Two Patients). Canadian Society For
12. Bessette E, Ng M, Gill B, Resz I, Angus N, Lane D, Gariepy L, Pavenski K, Ochoa G, Cote J,
Goldman M. Weak D Type 67 in 4 Related Donors. Transfusion 2014; 54: 147A-8A.
13. Bicalho B, Jordan A, Norris PJ, Acker J. Red Cell Concentrate Microvesicles Vary with Component
Separation Method. Transfusion 2014; 54: 92A-3A.
14. Bigham BL, Aguirre E, Choong K, Parker MJ. Determining the Timeliness of Key Resuscitative
Interventions among Pediatric Patients Treated for Septic Shock at a Pediatric Tertiary Care Hospital.
Circulation 2014; 130: A338.
15. Bigham M, Fortin D, Yee E, Dominguez M, Despins C, Fearon M. Response of a Regional Blood
Center to a Large Measles Outbreak in British Columbia, Canada. Transfusion 2014; 54: 268A.
16. Birch P, Leung D, Madana X, Mallon K, Hashimi M, Burke T, Milne T, McGuirl M. Qualification of
Refrigerators/Freezers. Canadian Society For Transfusion Medicine Website 2014.
17. Blake J, Hardy M. Evaluating the Impact of Shorter Shelf Life for Red Blood Cells with a Generic
Simulation. Canadian Society For Transfusion Medicine Website 2014.
18. Blake J, Hardy M. Evaluating the Impact of Shorter Shelf Life for Red Blood Cells with a Generic
Simulation. Industrial and Systems Engineering Research Conference - Conference Proceedings
Website 2014.
19. Bloch E, Sakac D, Branch H, Branch D. Warm Autoimmune Hemolytic Anemia - an Exacerbation of
Normal Red Blood Cell Senescence. Vox Sang 2014; 107: 17.
20. Bloch E, Sakac D, Branch H, Cserti-Gazdewich C, Pendergrast J, Pavenski K, Branch D. Western
Immunoblotting as a New Tool for Investigating Dat Negative Autoimmune Hemolytic Anemias. Vox
Sang 2014; 107: 173.
21. Briard JG, Gardiner E, Afagh M, Ben RN. The Design of Small Molecule Ice Recrystallization
Inhibitors for Use as Cryopreservatives. Cryobiology 2014; 69: 513.
22. Burgess A, Dubey S, Nhan T, Aubert I. Focused Ultrasound-Mediated Blood-Brain Barrier Opening in a
Mouse Model of Alzheimer's Disease. Canadian Association for Neuroscience Conference Website
2014.
23. Burgess A, Dubey S, Nhan T, Aubert I, Hynynen K. Safety and Efficacy of Blood-Brain Barrier
Disruption with Focused Ultrasound in a Mouse Model of Alzheimer's Disease. International Society for
Therapeutic Ultrasound Website 2014.
24. Burgess A, Dubey S, Bolewska-Pedyczak E, Gariepy J, Aubert I, Hynynen K. Focused UltrasoundMediated Antibody Delivery through the Blood-Brain Barrier for the Detection and Treatment of
Alzheimer's Disease. Society for Neuroscience Conference Website 2014.
xv
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
Chargé S, Walsh G. Bridging the Gap: Knowledge Mobilization and Transfusion Medicine Research.
Chen D, Schubert P, Devine D. Application of Proteomics Analysis to Red Blood Cell Changes Induced
by Pathogen-Reduction Technology. Transfusion 2014; 54: 76A-7A.
Chen Z, Schubert P, Culibrk B, Devine D. P38map-Kinasemediated Apoptotic Development in Platelets
Upon Riboflavin/Ultraviolet Light Treatment. Transfusion 2014; 54: 82A-3A.
Clarke G, Blain H, Onell R, Nahirniak S. Group O RBC Utilization in Non-Group O Patients Canadian
Society For Transfusion Medicine Website 2014.
Cook G, Clarke G. Are You My Mother? A Blood Group Discrepancy Study from an Obstetrical
Hospital. Canadian Society For Transfusion Medicine Website 2014.
Cote J, Whitteker t, Pigeau S, Scalia V, Goldman M. Evaluation of Progenika Id Core Xt Assay for
RBC Genotyping. Canadian Society For Transfusion Medicine Website 2014.
da Silveira Cavalcante L, Acker J, Holovati J. The Effect of Additive Solutions on Rat and Human Red
Blood Cells Following Blood Component Manufacturing. Canadian Society For Transfusion Medicine
Website 2014.
Da Silveira Cavalcante L, Acker JP, Holovati J. Stabilizing Effect of Liposomes on Rat Red Blood Cell
Membrane Quality Is Treatment-Time Dependent. Cryobiology 2014; 69: 516.
Devine D. Isn't There a Better Way to Make Blood Safety Decisions? Vox Sang 2014; 107: 7.
Doncaster C, Webert K, Gaffney V, Bourque L. Bloodbrief: Increasing Awareness and Influencing
Practice. Canadian Society For Transfusion Medicine Website 2014.
Dubey S, Burgess A, McLaurin J, Branch D, Hynynen K, Aubert I. The Delivery of Intravenous
Immunoglobulin to the Brain by Focused Ultrasound Guided by Magnetic Resonance Imaging: A
Therapeutic Approach for Alzheimer's Disease. Society for Neuroscience Conference Website 2014.
Eltringham-Smith L, Lei X, Reheman A, Pryzdial EL, Ni H, Sheffield W. Fibrinogen but Not Factor
VIII Levels Determine the Ability of Transfused Plasma to Reduce Bleeding in a Novel Mouse Model.
Eltringham-Smith LJ, Lei X, Reheman A, Lambourne MD, Pryzdial E, Ni H, Sheffield W. Transfused
Plasma Lacking Factor VIII (FVIII) but Not Fibrinogen Restores Hemostasis in Coagulopathic Mice.
Fearon M, Scalia V, O’Brien S, Bigham M, Andonov A, Weger S, Bernier F, Dubuc S, Delage G,
Germain M. Seroprevalence of Babesia and Hepatitis E in Canadian Blood Donors. Transfusion 2014;
54: 27A.
Fearon M, Scalia V, O'Brien SF, Bigham M, Andonov A, Weger S, Bernier F, Dubuc S, Delage G,
Germain M. Babesia and Hepatitis E Seroprevalence in Canadian Blood Donors. Can J Infect Dis Med
Microbiol 2014; 25: e38.
Fearon M, Scalia V, O'Brien SF, Bigham M, Andonov A, Weger S, Bernier F, Dubuc S, Delage G,
Germain M. Babesia and Hepatitis E Seroprevalence in Canadian Blood Donors. Canadian Society For
Foley SR, Rock G, Barth D, Arnold DM, Webert KE, Yenson PR, Kelton JG, Clark WF, Li L. A
Phase II Study Evaluating the Efficacy of Rituximab in the Management of Patients with Relapsed or
Refractory TTP. Blood 2014; 124: 4191.
Gerges H, Cembrowski G, Clarke G, Yakimec J. The R4sdi, X1.5sdi, and 75%Ae Rule Combination Can
Efficiently Interpret Proficiency Testing (PT) Data Produced by Highly Precise Hematology Analyzers.
Int J Lab Hematol 2014; 36: 128.
Gibson G, Chapman K, Mosewich R, Boulton P, Petraszko T, Li C, Premji S, Darnel S, Gee A,
Damielson J. Bc Intravenous Immune Globulin Neuromuscular Neurology Program - One Year Later.
Giwa S, Tocchio A, Acker J, Woods E. Catalyzing Cryopreservation Breakthroughs to Save Millions of
Lives. Cryobiology 2014; 69: 523.
Goldman M, Lane D, Gill B, Fransishyn K, Fallis R. Availability of Kell Negative Units for
Transfusion to Females under Age 45. Canadian Society For Transfusion Medicine Website 2014.
Guo L, Aslam R, Zhao Y, Speck ER, Ni H, Semple JW. CD20 B Cell Depleting Therapy Is Associated
with up-Regulation of Cd8+Cd25highfoxp3+ T Regulatory Cells in a Murine Model of Immune
Thrombocytopenia (ITP). Blood 2014; 124: 2785.
Hannon J, Caruk B, Clarke G. Serological Findings Related to Treatment with a Human Monoclonal
Antibody (Daratumumab) in Patients with Advanced Plasma Cell Myeloma. Transfusion 2014; 54:
162A.
Hannon J, Barr G, Clarke G. Antenatal Genotyping on Maternal Blood Samples - the CBS Edmonton
Experience. Canadian Society For Transfusion Medicine Website 2014.
xvi
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
Hou Y, Reheman A, Li BX, Dai X, Yang Z, Qian F, Zhang G, Xu Z, Liu J, Liang C, Zhao Y, Shen J,
Zhou H, Wang Y, Marshall AH, Lei X, Zarpellon A, Vanhoorelbeke K, Ruggeri Z, Ni H. Development
of a Novel Antithrombotic Therapy Targeting Platelet Gpibα: Assessment of Anfibatide in Vitro and in
Phase I Clinical Trial. Arteriosclerosis, Thrombosis, and Vascular Biology 2014; 34: A499.
Hysi E, Strohm EM, Berndl E, Acker J, Kolios MC. Assessing Storage-Induced Red Blood Cell
Lesions Using Photoacoustic Measurements of Oxygen Saturation and Frequency Content of Pa Signals.
IEEE International Ultrasonics Symposium Website 2014: 352.
Ismail A, Mierzejewska KA, Janowska-Wieczorek A, Turner AR, Ratajczak MZ, Kucia M. Novel
Evidence That Pituitary Gonadotropins Directly Stimulate Human Leukemic Cells—Studies on Myeloid
Cell Lines and Primary Patient AML and CML Cells. Blood 2014; 124: 2204.
Jen CC, Lazarus A. Evidence against a Simple Relationship between the Ability of Anti-RBC
Antibodies to Induce Anemia and the Amelioration of Passively-Acquired Murine ITP. Canadian
Jen M, Lazarus A. Evidence against a Simple Relationship between the Ability of Anti-RBC
Antibodies to Induce Anemia and the Amelioration of Passively-Acquired Murine ITP. Vox Sang 2014;
107: 171.
Johnson L, Hyland R, Tan S, Acker J, Marks DC. Determining the Role of Hydroxyethyl Starch for
Supporting the Quality of Cryopreserved Platelets Following Thawing and Reconstitution. Transfusion
2014; 54: 86A.
Johnson L, Schubert P, Tan S, Devine D, Marks DC. Glucose Is Required to Prevent Platelet Apoptosis
During Extended Storage in SSP+. Transfusion 2014; 54: 40A.
Jordan A, Chen D, Devine D, Acker J. Using Blood Bank Quality Control Data to Analyze
Manufacturing and Donor Variability. Transfusion 2014; 54: 42A.
Kalathottukaren MT, Shenoi RA, Benjamin LF, Rosell F, Kizhakkedathu JN, Pryzdial ELG. A
Universal Heparin Antidote with Negligible Effect on Fibrin(Ogen) and Plasma Coagulation. Blood
2014; 124: 4231.
Katz L, Benjamin RJ, Tomasulo PA, Goldman M. Interventions for Vasovagal Reactions (Vvrs) at
Alliance of Blood Operator (ABO) Blood Establishments (Bes): An International Survey for the ABO
Medical Working Group. Transfusion 2014; 54: 110A-1A.
Keir A, Hansen A, Jankov R, Callum J, Acker J. Co-Infusion of Dextrose-Containing Solutions and
Red Cells Concentrates Does Not Adversely Affect in Vitro Red Blood Cell Quality. J Paediatr Child
Health 2014; 50: 91.
Klein KB, Acker J. Technical Aspects of RHD PCR Performed Directly from Blood Sample.
Kruse A, Sughroue AM, Morrissey P, Tchatchouang C, Zhu G, Izak M, Ni H, Bussel JB. Response to
TPO-Receptor Agonists: Role of Immature Platelet Fraction and Anti-Gp1b. Blood 2014; 124: 4190.
Leiby D, O’Brien S, Seed C, Castro E, Wendel S, Delage G, Oliveras S, Devare S, Hardiman T,
Nakhasi H. Assessing the Global Reach, Risk and Mitigation Strategies Associated with Transfusion
Transmitted Parasites. Vox Sang 2014; 107: 20.
Li J, van der Wal D, Zhu G, Yougbare I, Grozovsky R, Ma L, Vadasz B, Ruan M, Zhu L, Zeng Q,
Leytin V, Hoffmeister K, Freedman J, Ni H. Anti-Gpiba Mediated Platelet Desialylation and Activation:
A Novel Fc-Independent Platelet Clearance Mechanism and Potential Therapeutic and Diagnostic
Target in ITP. Vox Sang 2014; 107: 27.
Li J, van der Wal DE, Zhu G, Xu M, Yougbare I, Ma L, Vadasz B, Grozovsky R, Ruan M, Zhu L, Zeng
Q, Tao L, Zhai Z-m, Peng J, Hou M, Leytin V, Freedman JJ, Hoffmeister KM, Ni H. Platelet
Desialylation: A Novel Mechanism of Fc-Independent Platelet Clearance and a Potential Diagnostic
Biomarker and Therapeutic Target in Immune Thrombocytopenia. Blood 2014; 124: 467.
Lieberman L, Wang G, Jaffer A, Heddle N. A Retrospective Review of Platelet Refractoriness in a
Cohort of Pediatric Oncology Patients. Transfusion 2014; 54: 135A.
Luo A, Han B, Quinn K, Tullis E, Reheman A, Ni H, Slutsky A, Zhang H. Reelin Mediates the Human
Neutrophil Peptide-Induced Endothelial Dysfunction and Platelet Aggregation. Intensive Care Medicine
Experimental 2014; 2: P37.
Ma L, Simpson E, Li J, Xuan M, Xu M, Baker L, Zhu G, Chen P, Lazarus A, Semple J, Freedman J, Ni
H. Cd8+ T Cells Are Predominantly Protective in a Murine Model of Autoimmune Thrombocytopenia
and Is Required for Effective Steroid Therapy. Vox Sang 2014; 107: 27.
Ma L, Simpson EK, Li J, Xuan M, Xu M, Baker L, Shi Y, Zhu G, Chen P, Lazarus AH, Freedman JJ,
Ni H. Unveiling the Regulatory Role of Cd8+ T-Cells in the Pathogenesis and Effective Steroid
Treatment in ITP. Blood 2014; 124: 576.
xvii
69.
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
90.
91.
92.
Mallya S, Taha M, Ramirez-Arcos S. Characterization of Staphylococcus Epidermidis Strains Isolated
from Contaminated Platelets at Canadian Blood Services from 2008 to 2013. Transfusion 2014; 54:
203A-4A.
Marquez-Curtis LA, Xu A, Janowska-Wieczorek A. Post-Thaw Characterization of Cord BloodDerived Mesenchymal Stromal Cells Cryopreserved for up to Five Years. Cryobiology 2014; 69: 519.
Morden J, Cote J, Pigeau S, Lane D, Skeate R, Lau W, Campeau-Fleury L, Lomas-Francis C,
Goldman M. Identification of Anti-Ge Antibodies in Four Mothers. Canadian Society For Transfusion
Medicine Website 2014.
Nazi I, Arnold DM, Smith JW, Warkentin TE, Moore JC, Horsewood P, Kelton JG. Low Level
Platelet-Activating Antibodies in Patients Suspected of Having Heparin-Induced Thrombocytopenia but
Testing Negative in the ”Gold Standard” Functional Test. Blood 2014; 124: 2757.
Ni H. Mechanisms of Heart Attack and Stroke: Critical Roles of Platelets in Atherothrombosis. Curr
Res Cardiol 2014; 1: 50.
Nielsen R. Impact of the Consolidation of Quality-Control Laboratories from 10 to 2. Transfusion 2014;
54: 262A.
O’Brien S, Osmond L, Goldman M. Donor Compliance with the Criterion for Men Who Have Sex
with Men (MSM) Prior to Implementation of a 5-Year Deferral. Transfusion 2014; 54: 35A-6A.
O’Brien S, Delage G, Seed C, Pillonel J, Corbi C, Davison K, Kitchen A, Steele W, Leiby D. An
Assessment of Travel to Malaria Endemic Regions from Five Non-Endemic Countries. Vox Sang 2014;
107: 23.
O’Brien S, Osmond L, Choquet K, Yi Q, Goldman M. Donor Attention to Pre-Donation Reading
Materials. Vox Sang 2014; 107: 32.
Osmond L, O’Brien S, Goldman M. Staff and Donor Expectations before and after Implementing
Equestionnaire. Canadian Society For Transfusion Medicine Website 2014.
Parrish M, Vanspronsen R, Shea R, Clarke G. Simulation as a Tool in the Transfusion Medicine Lab to
Evaluate and Improve the Massive Hemorrhage Protocol. Canadian Society For Transfusion Medicine
Website 2014.
Pasha R, Alsheikh M, Pineault N. The Ex Vivo Hematopoietic-Regulatory Activities of Osteoblasts on
Human HSPC Vary as a Function of Their Maturation. Exp Hematol 2014; 42: S56.
Pasha R, Pineault N. Impact of Osteoblast Maturation on the Expansion of Umbilical Cord Blood Cells.
Transfus Med Rev 2014; 28: 167-8.
Pasha R, Pineault N. Impact of Osteoblast Maturation on the Expansion of Umbilical Cord Blood Cells.
Pineault N. Ex Vivo Differentiation of Cord Blood Stem Cells into Megakaryocytes and Platelets. Vox
Sang 2014; 107: 13.
Poseluzny D, Lagerquist O, Werstiuk G, Ourdev L, Slomp J, Nahirniak S, Clarke G. What Is the True
Cost of a Unit of Red Blood Cells? A Costing Model for Hospital Use. Canadian Society For
Pryzdial EL, Sutherland MR, Simon AY, Serrano K, Schubert P, Acker J. Dengue Virus Persists in
Stored Platelets and Red Blood Cells. Canadian Society For Transfusion Medicine Website 2014.
Qi X, Wagner A, Mnich T, Biscocho MJ, Lau K, Shehata N. High Incidence of Formation of
Additional Rh Antibodies in Rh(D)-Sensitized Patients after Intrauterine Transfusion. Transfusion 2014;
54: 18A.
Ramirez-Arcos S, Kou Y, Perkins HM, Yang L, Taha M, den Admirant MA, Halpenny M, Elmoazzen
H. Validation of Microbial Testing in Cord Blood at Canadian Blood Services. Transfusion 2014; 54:
23A.
Ramirez-Arcos S, Perkins H, Kumaran D, Kou Y. pH Decline over Time in Platelet Concentrates as an
Indicator of Bacterial Contamination. Transfusion 2014; 54: 206A.
Ramirez-Arcos S, Kou Y, Perkins H, Yang L, den Admirant M, Halpenny M, Elmoazzen H. Validation
of Sterility Testing of Cord Blood at Canadian Blood Services: Challenges and Results. Canadian
Reddy EC, Zhu G, Chen P, Reheman A, Lei X, Li J, Xu X, Freedman J, Ni H. PSI Domain of ß3
Integrin Has Endogenous Thiol Isomerase Function and Is a Novel Antithrombotic Therapeutic Target.
Arteriosclerosis, Thrombosis, and Vascular Biology 2014; 34: A54.
Reddy E, Zhu G, Chen P, Reheman A, Lei X, Xu X, Petruzziello T, Rui M, Freedman J, Ni H. PSI
Domain of Beta3 Integrin Contains Endogenous Thiol Isomerase Function That Can Be Inhibited by a
Pdi Inhibitor Bacitracin and Anti-PSI Monoclonal Antibodies. J Thromb Haemost 2014; 12: 71.
Rentas S, Belew M, Holzapfel N, Hope K. Musashi2 Regulates Human Hematopoietic Cell SelfRenewal. ISSCR Website 2014.
xviii
93.
94.
95.
96.
97.
98.
99.
100.
101.
102.
103.
104.
105.
106.
107.
108.
109.
110.
111.
112.
113.
Reyes LB, Amash A, Lazarus A. Antibody-Mediated Immune Suppression Induced by Anti-RBC
Antibodies Increases in Effectiveness When Mixtures of Monoclonal Antibodies Are Used. Canadian
Rose L, Kucharski C, Jayasooriya D, Marquez-Curtis L, Gul-Uludag H, Janowska-Wieczorek A,
Uludag H. Approaches for Improved Polymeric Gene Delivery to Umbilical Cord Blood-Derived
Mesenchymal Stromal Cells. Mol Therapy 2014; 22: S134.
Salib M, Clayden R, Clare R, Wang G, Warkentin TE, Crowther MA, Lim W, Arnold DM. Difficulties
in Establishing the Cause of Thrombocytopenia among Ambulatory Patients Referred to Hematology:
An Agreement Study. Blood 2014; 124: 3521.
Schubert P, Culibrk B, Arbaeen AF, Devine D. Fas Receptor Signaling in Platelets Is Involved in
Platelet Clot Fibrinolysis. Transfusion 2014; 54: 20A.
Schubert P, Culibrk B, Karwal S, Devine D. Kinesin-Dependent Transport of Stress Granule into
Microparticles During Platelet Apoptosis. Transfusion 2014; 54: 20A.
Schubert P, Culibrk B, Karwal S, Serrano K, Levin E, Bu D, Bhakta V, Sheffield W, Goodrich R,
Devine D. Whole Blood Treated with Riboflavin/UV Light: Quality Assessment of All Blood
Components Produced by the Buffy Coat Method During Storage. Vox Sang 2014; 107: 123-4.
Schubert P, Karwal S, Culibrk B, Devine D. Timing of Pathogen Inactivation May Improve Platelet
Quality Retention. Vox Sang 2014; 107: 44.
Shehata N, Ducharme R, Forster A, Lawrence N, Rothwell DM, Malinowski AK, Fergusson DA,
Tinmouth A, Wilson K. Transfusion Trends and Predictors of Transfusion in Obstetrical
Hospitalizations. Transfusion 2014; 54: 186A.
Sutherland MR, Simon AY, Serrano K, Schubert P, Acker J, Pryzdial E. Dengue Virus Persists in
Stored Platelets and Red Blood Cells. Transfus Med Rev 2014; 28: 167.
Taha M, Ramirez-Arcos S, Maurer E. Bacterial Detection in Whole Blood Using Dynamic LightScattering Technology. Transfusion 2014; 54: 207A.
Taha M, Kou Y, Perkins H, Ramirez-Arcos S. Antimicrobial Activity of Blood Components. Canadian
Traore AN, Chan A, Warner M, Iorio A, Wu J, Stoffman J, Tinmouth A, Teitel J, Heddle N, Walker I.
Factor VII Deficiency Patients: 5 Years Factors Concentrates Utilization Trend Based on the Canadian
Hemophilia Assessment and Resource Management System (CHARMS). Haemophilia 2014; 20: 105.
Unrau J, Hrytzak J, Bigham M. A "Transparent Blood Inventory" Reporting System to Better Manage
Red Blood Cell Inventory During a Blood Supply Disruption. Canadian Society For Transfusion
Medicine Website 2014.
Uzicanin S, O'Brien SF, Goldman M. Impact of Updated Letter for Donors with Low Hemoglobin.
Wang Y, Reheman A, Spring C, Kalantari J, Marshall A, Wolberg A, Gross P, Weitz J, Rand M,
Freedman J, Mosher D, Ni H. Plasma Fibronectin Is a Vital Supportive Factor in Hemostasis and a
Unique Self-Limiting Regulator in Thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology
2014; 34: A35.
Webert K, Doncaster C, Romans R, Bourque L, Brace R, Coovadia A, Fawcett J, Harris V, Paulson D,
Tremblay D, Unrau J. Trends in the Use of Feiba and Recombinant Factor Viia. Canadian Society For
Webert K, Shavrnoch D, Howe D. Trends in the Issues of Blood Products from Canadian Blood
Services. Canadian Society For Transfusion Medicine Website 2014.
Westhoff CM, Hannon J, Clarke G, Cote J, Goldman M, Lane D, Vege S, Lomas-Francis C, Ochoa
G. A Weak D Phenotype Discovered in Nine Patients in Western Canada Due to a Nucleotide 1187c>G
(Pro396Arg) Change in RHD. Transfusion 2014; 54: 30A.
Xu X, Ju L, Spring CM, Yang H, Reheman A, Wang Y, Zhang H, Yang Y, Reddy EC, Song J, Zhu G,
Lei X, Lang S, Chen P, Jin JW, Connelly P, She Y, Cyr T, Zhu C, Freedman J, Tso P, Davidson S, Ni
H. Apolipoprotein a-IV Is a ß3 Integrin Ligand and an Endogenous Inhibitor of Platelets: Novel
Mechanisms of Prevention and Treatment for Atherothrombosis. Arteriosclerosis, Thrombosis, and
Vascular Biology 2014; 34: A225.
Xu X, Spring CM, Ju L, Wang Y, Reheman A, Yang H, Jin JW, Lei X, Yang Y, Reddy EC, Chen Y,
Chen P, Zhu G, Marchese P, Zarpellon A, Zhang H, She Y, Cyr T, Zhu C, Freedman J, Tso P, Davidson
S, Ruggeri ZM, Ni H. Apolipoprotein Α-IV Is a Novel Ligand of Platelet Αiibβ3 Integrin and an
Endogenous Thrombosis Inhibitor: Measurement of Single-Molecular Interactions by Biomembrane
Force Probe. Blood 2014; 124: 92.
Xu X, Wang Y, Spring CM, Ju L, Reheman A, Jin JW, Yang H, Chen P, Lei X, Yang Y, Chen Y, Zhang
H, Zhu G, Marchese P, Zarpellon A, She Y, Cyr T, Zhu C, Connelly P, Freedman J, Tso P, Davidson S,
xix
Ruggeri ZM, Ni H. Apolipoprotein a-IV Is a Novel Ligand of Platelet Beta3 Integrins and an
Endogenous Inhibitor of Thrombosis. 2nd Cardiovascular Forum for Promoting Centers of Excellence
and Young Investigators Website 2014: 37.
114. Yan Y, Jing M, Jinju T, Liyi C, Yin S, Ni H, Wenhua L. Plant Food Anthocyanins Induced Platelet
Apoptosis Via Bcl-2/Bcl-Xl Pathway. Blood 2014; 124: 4988.
115. Yougbare I, Lang S, Yang H, Chen P, Zhao X, Tai W-S, Zdravic D, Vadasz B, Li C, Piran S, Marshall
AH, Zhu G, Tiller H, Killie MK, Boyd S, Leong-Poi H, Skogen B, Adamson SL, Freedman J, Ni H.
Maternal Anti-Platelet Β3 Integrin Antibodies Impair Angiogenesis and Cause Intracranial Hemorrhage
in Fetal and Neonatal Alloimmune Thrombocytopenia. Blood 2014; 124: 2772.
116. Zeller M, Cserti-Gazdewich C, Delage G, Heddle N. Donath-Landsteiner Testing: A Retrospective
Review of Testing During Seven Years at a Large Academic Health Center and Results of a National
Survey. Transfusion 2014; 54: 225A.
Canadian Blood Services Circular of Information
1.
Jenkins C. Platelets. Circular of Information For the Use of Human Blood Components 2014.
2.
Jenkins C. Red Blood Cells, Leukocytes Reduced (LR). Circular of Information For the Use of Human
Blood Components 2014.
Canadian Blood Services Website Publications
1.
Acker JP. ResearchUnit: A Sweet Solution for Infant Transfusions? transfusionmedicine.ca website
2014.
2.
Canadian Blood Services. A Guide to Reporting Adverse Transfusion Events. transfusionmedicine.ca
website 2014.
3.
Goldman M. Iron Status in Canadian Blood Services Donors. transfusionmedicine.ca website 2014.
4.
Goldman M. ResearchUnit: Protecting Our Life Blood: Iron Deficiency in Canadian Blood Donors.
5.
Ni H. ResearchUnit: Plasma Fibronectin: Keeping the Delicate Balance between Bleeding and Clotting.
6.
7.
8.
Ramirez-Arcos S. ResearchUnit: Dodging Disinfection: Biofilm-Forming Skin Bacteria Can Resist
Disinfectants. transfusionmedicine.ca website 2014.
9.
Schubert P. ResearchUnit: Pathogen Inactivation for Safer Blood Transfusion: What Are the
Limitations? transfusionmedicine.ca website 2014.
10. Scott MD. ResearchUnit: Using Immunocamouflage to Fool the Immune System.
11. Semple J. ResearchUnit: Research into TRALI Therapies Gene Therapy Results That Are a Tad
Interesting! transfusionmedicine.ca website 2014.
12. Serrano K. ResearchUnit: Making the Cut: Protein Breakdown in Platelets During Storage.
13. Skeate R, Goldman M. Phenotype Matching for Sickle Cell Patients: A Review and Recommendations
for Transfusion Practice. transfusionmedicine.ca website 2014.
14. Webert K, Hume H, Revised by Clarke G and Hannon J. Hdfn and Perinatal Immune
Thrombocytopenia. In Clinical Guide to Transfusion. Edited by Clarke G, Charge SB. Published in
transfusionmedicine.ca by Canadian Blood Services, 2015.
15. Young D. Emergency Transfusion. In Clinical Guide to Transfusion. Edited by Clarke G, Charge S.
Published in transfusionmedicine.ca by Canadian Blood Services, 2014.
Technical Reports
1.
Acker J, Yi QL. Bag RFP PV - Statistical Analysis. Internal report submitted to Canadian Blood
Services, Chantal Couture, Project Manager and Wanda Lefresne, Associate Director 2014.
2.
Acker J, Yi QL. Blood Packs and Platelet Pooling Set Replacement Project - Sample Size and Testing
Specifications Pooled Platelets. Internal report submitted to Canadian Blood Services 2014.
3.
Acker J, Yi QL. Hespan Replacement - Technical Report. Internal report submitted to Canadian Blood
Services 2014.
4.
Acker J, Yi QL. Statistical Analysis Plan in Support of Process Validation for the Introduction of New
Macopharma Whole Blood Collection Packs and Platelet Pooling Sets. Internal Report submitted to
Wanda LaFresne, Associate Director, Production Process Management and Jennifer Davis, Project
Quality Lead 2014.
xx
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
Acker J, Yi Q, Hannach B. Introduction of the Acp-215 Cell Processor for Red Blood Cell Washing.
Internal technical report submitted to Canadian Blood Services 2015.
Acker JP. Elimination of Cooling Trays Project - Preliminary Study to Assess RBC Quality Internal
report submitted to Canadian Blood Services, Craig Jenkins, Manager, Quality Monitoring Program
2014.
Acker JP. HPC Apheresis Pentaspan Replacement (Phase 1) - Statistical Analysis. Internal report
submitted to Canadian Blood Services, Heidi Elmoazzen, Director, National Public Cord Blood Bank
2014.
Blake J. Modelling the Adult and Cord Stem Cell Registries: A Potpourri of Engineering Models.
Internal report submitted to Canadian Blood Services, Donna Killeen, Director of Strategic
Performance 2014.
Blake J. On the Use of a Generic Model for Evaluating Site-to-Site Inventory Transfers. Internal report
submitted to Canadian Blood Services, Rick Trifunov, Director of Supply Chain Operations Planning
2014.
Howell A, Acker J. Production of Matched Mock HPC-a Units from Residual Buffy Coats. Internal
report submitted to Hespan HPC-A project 2014.
Howell A, Acker J. Compolab Hemoglobinometer Evaluation. Internal report submitted to Canadian
Blood Services, Susan Shimla, Collections Process Management 2015.
Mastronardi C, Acker J. Blood Packs and Platelet Pooling Set Replacement Project - Technical
Summary Report. Internal report submitted to Canadian Blood Services, Chantal Couture, Project
Manager 2014.
Mastronardi C, Acker J, Yi QL, Jenkins C. Imuflex WB Rp Grafter 1 Cationization Limits Study.
External report submitted to Terumo BCT, Dr Mike McAteer, Senior Scientist 2014.
McTaggart K. Unrelated Haematopoietic Stem Cell Transplantation Performance - International
System Benchmarks. Internal report submitted to Canadian Blood Services, Stem Cell Strategy Refresh
2014.
Ramirez-Arcos S. Bacterial Detection Testing - Proficiency Test Kits and Proficiency Testing Results
Reports. Internal report submitted to Canadian Blood Services, Wanda Lefresne, Associate Director,
Production Process Management 2014.
Ramirez-Arcos S. The Effects of Room Temperature Exposure on Red Blood Cell Units. Internal
report submitted to Canadian Blood Services, Supply Chain 2014.
Ramirez-Arcos S. Evaluation of Alternative Skin Disinfection Methods for Donors Allergic to
Chlorhexidine. Internal report submitted to Canadian Blood Services, Mindy Goldman, Medical
Director, Donor and Clinical Services 2014.
Ramirez-Arcos S. Evaluation of the Efficacy of the Mirasol Pathogen Reduction Technology System to
Eradicate Biofilm-Forming Bacteria. External report submitted to Terumo BCT, Dr Susanne Marschner,
Director Global Scientific Affairs 2014.
Ramirez-Arcos S. Transfusion Reaction Lb# 98417 Guelph General. Internal report submitted to
Canadian Blood Services, Supply Chain and Medical Services 2014.
Ramirez-Arcos S. Certificate of Conformance - BPA and BPN Lots. Internal report submitted to
Canadian Blood Services, Quality Assurance 2014-2015.
Ramirez-Arcos S, Thibault L. The Effects of Room Temperature Exposure on Bacterial Growth in
RBC Units. External report submitted to Canadian Standards Association Working Group on the 30minute rule 2014.
Sheffield W. New Plasma Protein Product Report on Alprolix. Internal report submitted to Canadian
Blood Services, Peter Saunders, Associate Director, National Operations 2014.
Sheffield W. New Plasma Protein Product Report on Eloctate. Internal report submitted to Canadian
Blood Services, Peter Saunders, Associate Director, National Operations 2015.
Webert K. Proposal for the Utilization of Blood and Blood Products. External report submitted to the
Conference of Deputy Ministers of Health 2014.
Theses
1.
De Asis KG. Novel Mechanisms of Fibrinolysis in Health and Disease. Department of Experimental
Medicine. MSc. Supervisor: Pryzdial ELG. University of British Columbia; 2014.
2.
Hardy M. Simulation of a Reduced Red Blood Cell Shelf Life. MASc. Supervisor: Blake J. Dalhousie
University; 2015.
3.
Price D. The Effects of Polymer-Mediated Immunocamouflage on Allorecognition of Blood Cells.
Department of Pathology and Laboratory Medicine. PhD. Supervisor: Scott MD. University of British
Columbia; 2014.
xxi
Appendix III: Health Canada Financial
Contribution
Summary of Expenditures – April 1, 2014, to March 31, 2015
Schedule 1: Overview
Operating funds (Schedule 2)
Funding programs (Schedule 3)
Total
1,378,895
5,508,602
$6,887,497
Total
561,857
446,458
362,054
8,526
$1,378,895
Schedule 2: Operating Funds
Centre for Innovation programs administration
NetCAD operations
Intellectual property protection and other legal activities
Capital purchases
Schedule 3: Funding programs
Canadian Blood Services/CIHR partnership operating grants
Canadian Blood Services/CIHR new investigator program and fellowship
Canadian Blood Services intramural operating grants
James Kreppner fellowship in blood system studies
Kenneth Fyke award
Small projects funding
Graduate fellowship
Postdoctoral fellowship
Summer internship
Program Support Award for Canadian transfusion medicine and science
research
Additional funding for research projects
2,812,091
75,000
840,757
75,000
89,588
29,000
398,225
278,128
63,472
699,905
Total
147,435
$5,508,602
Notes:
Funding programs includes capital expenditures under $10,000.
xxii

Centre for Innovation Progress Report

Transcription

Similar documents

COMRADERY FROM COAST-TO

Druze panel Sep 29 REGISTER

Econiche House

List of Canadian bi#161AC38

INTRODUCTION During the Second World War, the role of women

Canada`s Landform Regions

NISSAN UKE! JUKE! - Canadian Direct Insurance

direct to you! - Canadian Direct Insurance

Military Service Recognition Book

Blood Transfusions for Anemia in the Hospital (ASH)